株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

服薬アドヒアランスの世界市場:スマートデリバリーデバイスおよびスマート容器

Global Drug Adherence Market: Focus on Smart Delivery Devices (Smart Inhalers, Injectors, Wearable Injectors, Pills) and Smart Accessories (Medication Dispensers, Pill Bottles / Boxes, Blister Packs)

発行 ROOTS ANALYSIS 商品コード 745209
出版日 ページ情報 英文 450 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.53円で換算しております。
Back to Top
服薬アドヒアランスの世界市場:スマートデリバリーデバイスおよびスマート容器 Global Drug Adherence Market: Focus on Smart Delivery Devices (Smart Inhalers, Injectors, Wearable Injectors, Pills) and Smart Accessories (Medication Dispensers, Pill Bottles / Boxes, Blister Packs)
出版日: 2018年10月26日 ページ情報: 英文 450 Pages
概要

医療業界では、服薬アドヒアランスへの関心が高まっています。米国では、小売業者による年間約40億の処方薬のうち、医師の指示通りに患者が服薬していないケースが、およそ50%にもなると推測されています。

当レポートでは、服薬アドヒアランス向上 (服薬遵守) 市場について調査分析し、市場の現状、規制情勢、主要企業のプロファイル、ケーススタディ、競争力分析などについて、体系的な情報を提供しています。

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 スマートドラッグデリバリーデバイス:現在の市場情勢

  • 概要
  • スマートドラッグデリバリーデバイス:市場全体の情勢

第5章 スマートアクセサリーデバイス・パッケージングシステム:現在の市場情勢

  • 概要
  • スマートアクセサリーデバイス:市場全体の情勢
  • コンプライアンスパッケージングシステム:市場全体の情勢

第6章 コネクテッドドラッグデリバリーシステムの規制情勢

  • 概要
  • 北米
  • 欧州
  • ラテンアメリカ
  • アジア太平洋地域
  • 中東
  • コネクテッドデバイス:安全性、有効性、性能の実証
  • コネクテッドデバイス:取得データの安全性の確保

第7章 ドラッグデリバリーデバイス:企業プロファイル

  • 概要
  • Adherium
  • BIOCORP
  • nGageIT Digital Health
  • Proteus Digital Health
  • SOOIL Development
  • Ypsomed

第8章 アクセサリーデバイス:企業プロファイル

  • 概要
  • AARDEX Group
  • Information Mediary
  • MedMinder Systems
  • Philips
  • Tinylogics
  • Vaica

第9章 ケーススタディ

  • 概要
  • ケーススタディ1:糖尿病
  • ケーススタディ2:喘息
  • ケーススタディ3:関節リウマチ

第10章 製品競争力分析

  • 概要
  • 調査手法
  • 全体の製品競争力分析

第11章 資金と投資分析

第12章 パートナーシップと提携

第13章 モバイルアプリケーションによる服薬アドヒアランス

第14章 市場の予測

第15章 結論

第16章 エグゼクティブの考察

  • 概要
  • AARDEX Group
  • AceAge
  • AdhereTech
  • Amiko Digital Health
  • Cognita Labs
  • etectRx
  • PharmAdva
  • Popit Technologies
  • Wealth Taxi
  • 小企業企業

第17章 付録1

第18章 付録2

目次
Product Code: RA100123

Poor adherence to prescribed medications is a growing concern in the healthcare industry and is believed to be associated with negative health outcomes, inflated medical expenses, loss in productivity and, in certain cases, proves fatal as well. It has been estimated that, of the ~4 billion annual prescriptions filled by the retailers in the US, approximately 50% are not taken by patients in accordance to physicians' instructions. According to the US Centers for Disease Control and Prevention (CDC), failure to comply to prescribed treatment regimens has been identified as the cause of 125,000 premature deaths, up to 69% of all rehospitalizations, and results in approximately USD 100-300 billion worth of avoidable annual healthcare spending. Further, the US pharmaceutical industry alone is estimated to suffer a loss of approximately USD 188 billion per year, due to low adherence to prescribed medications.

Lack of compliance to therapy is particularly prevalent among elderly patients suffering from chronic clinical conditions, such as cardiovascular disorders, metabolic disorders (e.g., diabetes), neurological and central nervous system related disorders (e.g., multiple sclerosis and Parkinson's disease) and respiratory disorders (e.g., asthma and chronic obstructive pulmonary disease). It is estimated that overall cost of treatment for non-adherent patients is at least twice as high as patients who adhere to recommended therapy regimens. Studies have demonstrated that every one percent improvement in medication adherence can help the US healthcare industry save up to USD 2 billion, resulting in an increase in pharmaceutical revenues by ~USD 4 billion. As a result, several strategies have been / are being developed by pharmaceutical developers and healthcare providers to improve medication adherence. Such initiatives have been strengthened owing to the availability of connected devices and other digital solutions, which allow patients / healthcare providers to closely monitor and improve drug adherence.

Synopsis:

The ‘Drug Adherence Enhancement Market: Devices and Applications, 2018-2030 ’ report features an extensive study of the current landscape and future outlook of the growing market for smart medication adherence devices that are either already commercialized or under development. This burgeoning field presently offers a lot of opportunities to innovation-driven start-ups and investors. Amongst other elements, the report features:

  • A discussion on the current market landscape of smart drug delivery devices for medication adherence (which include smart inhalers, smart injectors, smart wearable injectors and smart pills), featuring information on the developers, along with details on key product specifications, namely audio / visual reminders, connectivity features (USB connection, Bluetooth and / or cellular network), availability of companion mobile application(s) and / or web portal(s), data storage / cloud platform options, and availability of battery backup / rechargeable batteries.
  • A discussion on the current market landscape of smart accessory devices for medication adherence (including smart medication dispensers, smart pill bottles / caps, smart pill boxes and smart blister packs), featuring information on the various developers, along with details on key product specifications. The section also presents a list of compliance packaging systems, along with information on their developers.
  • A summary of the various guidelines issued by regulatory authorities to govern the development and approval of combination products (drugs and smart devices) across different geographical regions.
  • Detailed profiles of some of the leading players in the industry (based on a proprietary shortlisting criteria) , highlighting a brief overview of the company, financial information (if available), details related to its products / offerings, clinical trial results, recent developments and a comprehensive future outlook.
  • Detailed case studies on the most common chronic disease indications, featuring disease epidemiology, an overview of the economic burden imposed due to non-adherence to prescribed treatment regimens and a history of drug development efforts along with details on the evolution of delivery devices / strategies for improving therapy adherence.
  • A comprehensive competitiveness analysis of connected smart drug delivery systems and smart accessory systems on the basis of supplier power and key product specifications.
  • An analysis of funding and investments made in companies focused in this domain; the analysis covers information on seed financing, venture capital financing, debt financing, other equity financing and grants / awards received by these companies.
  • An analysis of the partnerships that have been forged between companies in the recent past, covering acquisitions, treatment optimization agreements, distribution agreements, manufacturing and supply agreements, product improvement agreements, product development agreements, product commercialization agreements, licensing agreements, service alliances and other relevant deals inked in the period 2010-2018. It also highlights the number of intercontinental and intracontinental deals signed in the aforementioned time period.
  • A list of standalone mobile applications that have been developed / are being developed to enable patients to adhere to prescribed medication regimens, along with the USFDA's regulations related to such applications. It also includes details on the various articles / publications that have reported the results achieved by using mobile applications for improving medication adherence among patients.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. We have segmented the market by type of solution (smart drug delivery devices and smart accessory devices), type of product (smart inhalers, smart injectors, smart wearable injectors, smart pills, smart medication dispensers, smart pill bottles / caps and boxes, smart blister packs and others), therapeutic areas (metabolic disorders, cardiovascular disorders, neurological and central nervous system related disorders, respiratory disorders, and others), route of administration (oral, injectable, inhalable and others) and geography (North America, Europe, Asia-Pacific and rest of the world). To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:

  • Bernard Vrijens (Chief Executive Officer, AARDEX Group)
  • Spencer Waugh (Chief Executive Officer, AceAge)
  • Josh Stein (Chief Executive Officer, AdhereTech)
  • Duilio Macchi (Chief Executive Officer, Amiko Digital Health)
  • Gaurav Patel (Chief Technical Officer, Cognita Labs)
  • Tina Valbh (Strategy and Business Development (Advisor), etectRx)
  • Jonathan Sacks (Chief Executive Officer and Chairman, PharmAdva)
  • Timo Heikkilä (Co-Founder and Chief Operating Officer, Popit Technologies)
  • Moore Greenberg (Founder, Wealth Taxi)
  • Anonymous (Small-sized company)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights:

  • 1. Currently, over 60 smart drug delivery devices are either commercially available or are under development for improving adherence to medication. More than 50% of these devices are smart inhalers or smart injectors. Examples of smart inhalers and smart injectors include (in alphabetical order, no selection criteria) 3M™ Intelligent Control Inhaler (3M), BETACONNECT™ (Medicom Innovation Partner), eMDI™ (H&T Presspart), Flexi-Q eMU-P and Flexi-Q eMU-C (Elcam Drug Delivery Device), GoCap (Common Sensing), Propeller (Propeller Health), SMARTTURBO™, SMARTTOUCH™ and SMARTTOUCH™ AV (Adherium), and SmartPilot and YpsoMate Smart (Ypsomed).
  • 2. In addition, there are close to 75 smart accessory devices that are either commercially available or are under development. Of these, over 40% are smart medication dispensers. Noteworthy examples of such products include (in alphabetical order, no selection criteria)Evondos® E300 (Evondos), HERO (HERO Health), Maya™ and Jon™ (MedMinder Systems), MedaCube (PharmaAdva) and Philips Medido (Philips), Pillo (Pillo Health) and SIMPLEMED+ (Vaica).
  • 3. Around 70% of the companies that are involved in the development of smart drug delivery systems and smart accessory systems are small-sized players / start-ups (having less than 50 employees). Examples of such companies include (in alphabetical order, no selection criteria) Aerobit Health, Airbrio, Arthur Health, Cognita Labs, CuePath Innovation, DayaMed, etectRx, MedMinder Systems, PharmRight, Popit, Portal Instruments and Wealth Taxi.
  • 4. Over 50 compliance packaging systems are available to promote medication adherence among patients suffering from chronic clinical conditions; these include blister packs, pouches and dose cups. Companies engaged in the development of such products include (in alphabetical order, no selection criteria) Dispill-USA (Dispill® Multi-dose Packaging), Keystone Folding Box (Ecoslide-RX, Key-Pak® and Key-Pak Plus™), Omnicell (Opti-Pak™ and SureMed®), Parata Systems (Parata PASS Pack™) and TCGRx (AdherePac™ and AdhereCard™)
  • 5. Many standalone mobile applications are also available for improving compliance to prescribed therapeutic regimens. As of July 2018, over 200 such mobile applications, having user ratings of more than four, were available on Google Play Store. It is worth mentioning that more than 70% smart drug delivery and accessory devices that we came across have a supporting mobile application.
  • 6. Close to 180 partnerships have been inked between various stakeholders within the industry over the last few years; of these, over 100 collaborations were signed since 2016. Most of the deals that we came across were product development agreements (53%), signed between players to include new features in their products or advance their development programs. Examples of recently established deals include collaborations between Ypsomed and JDRF (August 2018), Adherium and Vitalus Health (August 2018), Amiko Digital Health and Luz Saúde (July 2018), Becton Dickinson and Helmer Scientific (June 2018), Common Sensing and Flex (May 2018), and Compliance Meds Technologies and Oracle Health Sciences (April 2018),
  • 7. Since 2001, nearly USD 2.5 billion has been invested in companies operating in the field of medication adherence. Interestingly, close to half of the total amount (USD 1.1 billion) was raised between 2015 and August 2018, indicating the rising interest of strategic investors in this domain. Examples of players that have managed to secure capital investments in multiple rounds include Proteus Digital Health, NantHealth, Tandem Diabetes Care, Propeller Health and Cellnovo.
  • 8. The drug adherence market is expected to grow at an annualized rate of more than 15.4% between 2018 and 2030. It is important to highlight that North America (primarily the US) and Europe currently capture the largest share of the overall market. This is followed by Asia-Pacific and rest of the world. As the industry matures, we expect the market in Asia-Pacific to grow owing to the sizable user base in the region.

Research Methodology:

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming 12 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of smart / connected devices that are being developed for improving medication adherence among patients.

Chapter 3 provides a general overview about medication adherence and the various methods / parameters used to measure and track patient compliance to prescribed therapeutic regimens. It also includes brief discussion on various types of non-adherence to therapy exhibited by patients and different factors that are considered to be responsible for such practices. In addition, the chapter features a detailed discussion on how non-adherence to therapy is impacting the health of patients and the overall healthcare industry. Further, it includes a brief discussion on various traditional and modern strategies for overcoming poor therapy adherence in patients. The chapter also provides information on the different initiatives that have been undertaken by various organizations to promote medication adherence.

Chapter 4 includes information on over 60 smart drug delivery devices that are either commercialized or under different stages of development for improving medication adherence. The chapter includes the information on the developer companies and the type of smart drug delivery product they offer; these include smart inhalers, smart injectors, smart wearable injectors, smart pills and other such devices. In addition, the chapter includes an analysis based on key product specifications, namely audio / visual reminders, connectivity features (USB connection, Bluetooth and / or cellular network), availability of companion mobile application, and companion web portal, data storage / cloud platform options and availability of battery backup / rechargeable battery.

Chapter 5 includes information on over 70 smart accessory devices that are either commercialized or under different stages of development for improving medication adherence. The chapter includes information on the developer companies and the type of smart accessory product they offer; these include smart medication dispensers, smart pill bottles / caps, smart pill boxes, smart blister packs and others. In addition, the chapter includes an analysis on key product specifications, namely audio / visual reminders, connectivity features (USB connection, Bluetooth, Wi-Fi and / or cellular network), availability of companion mobile application, and companion web portal, data storage / cloud platform options and availability of battery backup / rechargeable battery. Further, the chapter includes a brief overview on compliance packaging and a list of key players with expertise in this domain.

Chapter 6 provides information on various guidelines issued by regulatory authorities to govern the development and approval of combination products (drugs and smart devices) across different geographical regions such as North America, Europe, Latin America, Asia Pacific and the Middle East.

Chapter 7 features detailed profiles of some of the leading stakeholders in the smart drug delivery systems market. Each profile includes a brief overview of the company, financial information (if available), details related to its products / offerings, clinical trial results, recent developments and a comprehensive future outlook.

Chapter 8 features detailed profiles of some of the leading stakeholders in the smart accessory systems market. Each profile includes a brief overview of the company, financial information (if available), details related to its products / offerings, clinical trial results, recent developments and a comprehensive future outlook.

Chapter 9 features case studies on the most common disease indications across metabolic disorders, respiratory disorders and autoimmune disorders. Each case study features a detailed description of the disease, its epidemiology, an overview of the economic burden imposed due to non-adherence to prescribed treatments for the disease and history of drug development along with the evolution of delivery devices / strategies focused on improving therapy adherence.

Chapter 10 presents a product competitiveness analysis of all connected smart drug delivery systems and smart accessory systems on the basis of supplier power and key product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 11 provides information on the funding and investments that have been made in both smart drug delivery systems and smart accessory systems in the recent past. The chapter includes details on various types of capital investments, such as seed financing, venture funding, debt financing and grants, received by companies, highlighting the growing interest of the venture capital community and other strategic investors in this domain.

Chapter 12 features an analysis of the recent collaborations and partnerships that have been inked amongst players in this market, covering several partnership models, namely acquisitions, treatment optimization agreements, distribution agreements, manufacturing and supply agreements, product improvement agreements, product development agreements, product commercialization agreements, licensing agreements, service alliances and others, that have been adopted by industry stakeholders in this domain. It includes a world map representation of all the deals inked in this field in the period 2010-2018, highlighting both intercontinental and intracontinental partnership activity.

Chapter 13 provides a brief overview of the increasing prominence of mobile applications in the healthcare industry and the various regulations laid down by the USFDA for such applications. It includes a list of applications that are available at Google Play Store for helping patients adhere to prescribed medication regimens. The chapter also provides information on the various articles / publications, featuring results of studies aimed to demonstrate the benefits of using mobile applications for improving medication adherence among patients.

Chapter 14 presents a comprehensive market forecast, highlighting the future potential of the market till 2030 based on multiple parameters, such as prices of novel solutions, indication / region specific adoption trends, and competitive landscape. We have provided an informed estimate on the likely evolution of smart drug delivery devices and smart accessory devices. In addition, we have segmented the market by type of product (smart inhalers, smart injectors, smart wearable injectors, smart pills, smart medication dispensers, smart pill bottles / caps and boxes, smart blister packs and others), therapeutic areas (metabolic disorders, cardiovascular disorders, neurological and central nervous system related disorders, respiratory disorders and others), route of administration (oral, injectable, inhalable and others) and geography (North America, Europe, Asia-Pacific and rest of the world).

Chapter 15 summarizes the overall report. The chapter provides a list of the key takeaways and presents our independent opinion on the medication adherence market, specific to smart drug delivery systems and smart accessory systems, based on the research and analysis described in the previous chapters.

Chapter 16 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Bernard Vrijens (Chief Executive Officer, AARDEX Group), Spencer Waugh (Chief Executive Officer, AceAge), Josh Stein (Chief Executive Officer, AdhereTech), Duilio Macchi (Chief Executive Officer, Amiko Digital Health), Gaurav Patel (Chief Technical Officer, Cognita Labs), Tina Valbh (Strategy and Business Development (Advisor), etectRx), Jonathan Sacks (Chief Executive Officer and Chairman, PharmAdva), Timo Heikkilä (Co-Founder and Chief Operating Officer, Popit Technologies), Moore Greenberg (Founder, Wealth Taxi) and Anonymous (Small-sized company)

Chapter 17 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 18 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.1. Research Methodology
  • 1.2. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Medication Non-Adherence: A National Epidemic
  • 3.2. Medication Adherence and its Measurement
  • 3.3. Types of Medication Non-Adherence
    • 3.3.1. Factors Contributing to Non-Adherence
    • 3.3.2. Impact of Non-Adherence on Health of Patients and Healthcare Industry
  • 3.4. Improving Medication Adherence
    • 3.4.1. Traditional Interventions
    • 3.4.2. Modern Interventions
      • 3.4.2.1. Connected Devices
      • 3.4.2.2. Mobile Applications
      • 3.4.2.3. Gamification
      • 3.4.2.4. Compliance Packaging
  • 3.5. Key Initiatives to Improve Medication Adherence

4. SMART DRUG DELIVERY DEVICES: CURRENT MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Smart Drug Delivery Devices: Overall Market Landscape
    • 4.2.1. Distribution by Year of Establishment of Developers
    • 4.2.2. Distribution by Geographical Location of Developers
    • 4.2.3. Distribution by Size of Developers
    • 4.2.4. Distribution by Type of Devices
    • 4.2.5. Distribution by Mode of Drug Delivery
    • 4.2.6. Distribution by Key Device Specifications
      • 4.2.6.1. Audio / Visual Reminders
      • 4.2.6.2. Connectivity (USB, Bluetooth, or Cellular)
      • 4.2.6.3. Companion Mobile Application
      • 4.2.6.4. Companion Web Portal
      • 4.2.6.5. Data Storage / Cloud Platform
      • 4.2.6.6. Rechargeable Battery / Battery Backup
    • 4.2.7. Key Players
    • 4.2.8. Smart Inhalers
      • 4.2.8.1. Distribution by Year of Establishment of Developers
      • 4.2.8.2. Distribution by Geographical Location of Developers
      • 4.2.8.3. Distribution by Size of Developers
      • 4.2.8.4. Distribution by Key Device Specifications
    • 4.2.9. Smart Injectors
      • 4.2.9.1. Distribution by Year of Establishment of Developers
      • 4.2.9.2. Distribution by Geographical Location of Developers
      • 4.2.9.3. Distribution by Size of Developers
      • 4.2.9.4. Distribution by Key Device Specifications
    • 4.2.10. Smart Wearable Injectors
      • 4.2.10.1. Distribution by Year of Establishment of Developers
      • 4.2.10.2. Distribution by Geographical Location of Developers
      • 4.2.10.3. Distribution by Size of Developers
      • 4.2.10.4. Distribution by Key Device Specifications
    • 4.2.11. Smart Pills / Other Smart Devices
      • 4.2.11.1. Distribution by Year of Establishment of Developers
      • 4.2.11.2. Distribution by Geographical Location of Developers
      • 4.2.11.3. Distribution by Size of Developers
      • 4.2.11.4. Distribution by Key Device Specifications

5. SMART ACCESSORY DEVICES AND PACKAGING SYSTEMS: CURRENT MARKET LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Smart Accessory Devices: Overall Market Landscape
    • 5.2.1. Distribution by Year of Establishment of Developers
    • 5.2.2. Distribution by Geographical Location of Developers
    • 5.2.3. Distribution by Size of Developer
    • 5.2.4. Distribution by Type of Devices
    • 5.2.5. Distribution by Key Device Specifications
      • 5.2.5.1. Audio / Visual Reminders
      • 5.2.5.2. Connectivity (USB, Bluetooth, Wi-Fi, or Cellular)
      • 5.2.5.3. Companion Mobile Application
      • 5.2.5.4. Companion Web Portal
      • 5.2.5.5. Data Storage / Cloud Platform
      • 5.2.5.6. Rechargeable Battery / Battery Backup
    • 5.2.6. Key Players
    • 5.2.7. Smart Medication Dispensers
      • 5.2.7.1. Distribution by Year of Establishment of Developers
      • 5.2.7.2. Distribution by Geographical Location of Developers
      • 5.2.7.3. Distribution by Size of Developers
      • 5.2.7.4. Distribution by Key Device Specifications
    • 5.2.8. Smart Pill Bottles / Caps
      • 5.2.8.1. Distribution by Year of Establishment of Developers
      • 5.2.8.2. Distribution by Geographical Location of Developers
      • 5.2.8.3. Distribution by Size of Developers
      • 5.2.8.4. Distribution by Key Device Specifications
    • 5.2.9. Smart Pill Boxes
      • 5.2.9.1. Distribution by Year of Establishment of Developers
      • 5.2.9.2. Distribution by Geographical Location of Developers
      • 5.2.9.3. Distribution by Size of Developers
      • 5.2.9.4. Distribution by Key Device Specifications
    • 5.2.10. Smart Blister Packs
      • 5.2.10.1. Distribution by Year of Establishment of Developers
      • 5.2.10.2. Distribution by Geographical Location of Developers
      • 5.2.10.3. Distribution by Size of Developers
      • 5.2.10.4. Distribution by Key Device Specifications
    • 5.2.11. Other Smart Devices
      • 5.2.11.1. Distribution by Year of Establishment of Developers
      • 5.2.11.2. Distribution by Geographical Location of Developers
      • 5.2.11.3. Distribution by Size of Developers
      • 5.2.11.4. Distribution by Key Device Specifications
  • 5.3. Compliance Packaging Systems: Overall Market Landscape
    • 5.3.1. Distribution by Geographical Location of Developers
    • 5.3.2. Distribution by Size of Developers
    • 5.3.3. Distribution by Type of Packaging System
    • 5.3.4. Distribution by Key Specifications
      • 5.3.4.1. Distribution by Number of Doses per Pack
      • 5.3.4.2. Distribution by Availability of Other Key Features

6. REGULATORY LANDSCAPE FOR CONNECTED DRUG DELIVERY SYSTEMS

  • 6.1. Chapter Overview
  • 6.2. North America
    • 6.2.1. Regulatory Approval of Combination Products in the US
      • 6.2.1.1. Overview
      • 6.2.1.2. Historical Background
      • 6.2.1.3. Regulatory Bodies and their Role in Product Approval
    • 6.2.2. Regulatory Approval of Combination Products in Canada
      • 6.2.2.1. Overview
      • 6.2.2.2. Regulatory Bodies and Their Role in Product Approval
  • 6.3. Europe
    • 6.3.1. Regulatory Approval of Combination Products in Europe
      • 6.3.1.1. Overview
      • 6.3.1.2. Regulatory Bodies and Their Role in Product Approval
  • 6.4. Latin America
    • 6.4.1. Regulatory Approval of Combination Products in Brazil
      • 6.4.1.1. Overview
      • 6.4.1.2. Regulatory Bodies and Their Role in Product Approval
    • 6.4.2. Regulatory Approval of Combination Products in Mexico
      • 6.4.2.1. Overview
      • 6.4.2.2. Regulatory Bodies and Their Role in Product Approval
    • 6.4.3. Regulations of Combination Products in Argentina
      • 6.4.3.1. Overview
      • 6.4.3.2. Regulatory Bodies and Their Role in Product Approval
  • 6.5. Asia-Pacific
    • 6.5.1. Regulatory Approval of Combination Products in Japan
      • 6.5.1.1. Overview
      • 6.5.1.2. Regulatory Bodies and Their Role in Product Approval
    • 6.5.2. Regulation of Combination Products in South Korea
      • 6.5.2.1. Overview
      • 6.5.2.2. Regulatory Bodies and Their Role in Product Approval
    • 6.5.3. Regulatory Approval of Combination Products in Australia
      • 6.5.3.1. Overview
      • 6.5.3.2. Regulatory Bodies and Their Role in Product Approval
    • 6.5.4. Regulatory Approval of Combination Products in China
      • 6.5.4.1. Overview
      • 6.5.4.2. Regulatory Bodies and Their Role in Product Approval
    • 6.5.5. Regulations of Combination Products in India
      • 6.5.5.1. Overview
      • 6.5.5.2. Regulatory Bodies and Their Role in Product Approval
  • 6.6. Middle East
    • 6.6.1. Regulation of Combination Products in Saudi Arabia
      • 6.6.1.1. Overview
      • 6.6.1.2. Regulatory Bodies and Their Role in Product Approval
    • 6.6.2. Regulation of Combination Products in United Arab Emirates
      • 6.6.2.1. Overview
      • 6.6.2.2. Regulatory Bodies and Their Role in Product Approval
  • 6.7. Connected Devices: Demonstrating Safety, Effectiveness and Performance
  • 6.8. Connected Devices: Ensuring Security of Data Captured

7. DRUG DELIVERY DEVICES: COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. Adherium
    • 7.2.1. Company Overview
    • 7.2.2. Financial Information
    • 7.2.3. Product Portfolio
    • 7.2.4. Research Studies and Scientific Evidence
    • 7.2.5. Recent Developments and Future Outlook
  • 7.3. BIOCORP
    • 7.3.1. Company Overview
    • 7.3.2. Financial Information
    • 7.3.3. Product Portfolio
    • 7.3.4. Recent Developments and Future Outlook
  • 7.4. nGageIT Digital Health
    • 7.4.1. Company Overview
    • 7.4.2. Product Portfolio
    • 7.4.3. Recent Developments and Future Outlook
  • 7.5. Proteus Digital Health
    • 7.5.1. Company Overview
    • 7.5.2. Product Portfolio
    • 7.5.3. Research Studies and Scientific Evidence
    • 7.5.4. Recent Developments and Future Outlook
  • 7.6. SOOIL Development
    • 7.6.1. Company Overview
    • 7.6.2. Product Portfolio
    • 7.6.3. Recent Developments and Future Outlook
  • 7.7. Ypsomed
    • 7.7.1. Company Overview
    • 7.7.2. Financial Information
    • 7.7.3. Product Portfolio
    • 7.7.4. Recent Developments and Future Outlook

8. ACCESSORY DEVICES: COMPANY PROFILES

  • 8.1. Chapter Overview
  • 8.2. AARDEX Group
    • 8.2.1. Company Overview
    • 8.2.2. Product Portfolio
    • 8.2.3. Recent Developments and Future Outlook
  • 8.3. Information Mediary
    • 8.3.1. Company Overview
    • 8.3.2. Product Portfolio
    • 8.3.3. Recent Developments and Future Outlook
  • 8.4. MedMinder Systems
    • 8.4.1. Company Overview
    • 8.4.2. Product Portfolio
    • 8.4.3. Recent Developments and Future Outlook
  • 8.5. Philips
    • 8.5.1. Company Overview
    • 8.5.2. Financial Information
    • 8.5.3. Product Portfolio
    • 8.5.4. Research Studies and Scientific Evidence
    • 8.5.5. Recent Developments and Future Outlook
  • 8.6. Tinylogics
    • 8.6.1. Company Overview
    • 8.6.2. Product Portfolio
    • 8.6.3. Recent Developments and Future Outlook
  • 8.7. Vaica
    • 8.7.1. Company Overview
    • 8.7.2. Product Portfolio
    • 8.7.3. Research Studies and Scientific Evidence
    • 8.7.4. Recent Developments and Future Outlook

9. CASE STUDIES

  • 9.1. Chapter Overview
  • 9.2. Case Study I: Diabetes
    • 9.2.1. Disease Description
    • 9.2.2. Disease Statistics
    • 9.2.3. Economic Burden due to Non-Adherence
    • 9.2.4. Evolution of Drug Delivery / Connected Devices for Improving Adherence
  • 9.3. Case Study II: Asthma
    • 9.3.1. Disease Overview
    • 9.3.2. Disease Statistics
    • 9.3.3. Economic Burden due to Non-Adherence
    • 9.3.4. Evolution of Drug Delivery / Connected Devices for Improving Adherence
  • 9.4. Case Study III: Rheumatoid Arthritis
    • 9.4.1. Disease Overview
    • 9.4.2. Disease Statistics
    • 9.4.3. Economic Burden due to Non-Adherence
    • 9.4.4. Evolution of Drug Delivery / Connected Devices for Improving Adherence

10. PRODUCT COMPETITIVENESS ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Methodology
    • 10.2.1. Key Parameters and Methodology
  • 10.3. Overall Product Competitiveness Analysis
    • 10.3.1. Product Competitiveness Analysis for Smart Medication Dispensers
    • 10.3.2. Product Competitiveness Analysis for Smart Pill Packaging Systems
    • 10.3.3. Product Competitiveness Analysis for Smart Inhalers
    • 10.3.4. Product Competitiveness Analysis for Smart Injectors
    • 10.3.5. Product Competitiveness Analysis for Smart Wearable Injectors

11. FUNDING AND INVESTMENT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Types of Funding
  • 11.3. Drug Adherence Enhancement Market: Funding and Investment Analysis
    • 11.3.1. Analysis by Number of Instances
    • 11.3.2. Analysis by Amount Invested
    • 11.3.3. Analysis by Type of Funding
    • 11.3.4. Analysis by Number of Funding Instances and Amount Invested in Different Types of Devices
    • 11.3.5. Most Active Players
    • 11.3.6. Most Active Investors
  • 11.4. Concluding Remarks

12. PARTNERSHIPS AND COLLABORATIONS

  • 12.1. Chapter Overview
  • 12.2. Partnership Models
  • 12.3. Drug Adherence Enhancement Market: List of Partnerships and Collaborations
    • 12.3.1. Analysis by Year of Partnership
    • 12.3.2. Analysis by Type of Partnership
    • 12.3.3. Analysis by Geographical Activity
    • 12.3.4. Most Active Players: Analysis by Number of Partnerships
    • 12.3.5. Concluding Remarks

13. MEDICATION ADHERENCE WITH MOBILE APPLICATIONS

  • 13.1. Chapter Overview
  • 13.2. The Increasing Trend of Mobile Applications in Healthcare Industry
  • 13.3. USFDA Regulations for Mobile Medical Applications
  • 13.4. List of Mobile Applications for Improving Medication Adherence
  • 13.5. Medication Adherence with Mobile Applications: Clinical Research Evidence
    • 13.5.1. Distribution by Therapeutic Area

14. MARKET FORECAST

  • 14.1. Chapter Overview
  • 14.2. Forecast Methodology and Key Assumptions
  • 14.3. Global Drug Adherence Enhancement Market
    • 14.3.1. Global Drug Adherence Enhancement Market, 2018-2030 (By Value)
      • 14.3.1.1. Drug Adherence Enhancement Market for Smart Drug Delivery Devices, 2018-2030 (By Value)
      • 14.3.1.2. Drug Adherence Enhancement Market for Smart Accessory Devices, 2018-2030 (By Value)
      • 14.3.1.3. Drug Adherence Enhancement Market for Other Type of Devices, 2018-2030 (By Value)
    • 14.3.2. Global Drug Adherence Enhancement Market, 2018-2030 (By Volume)
      • 14.3.2.1. Drug Adherence Enhancement Market for Smart Drug Delivery Devices, 2018-2030 (By Volume)
      • 14.3.2.2. Drug Adherence Enhancement Market for Smart Accessory Devices, 2018-2030 (By Volume)
      • 14.3.2.3. Drug Adherence Enhancement Market for Other Type of Devices, 2018-2030 (By Volume)
      • 14.4. Global Drug Adherence Enhancement Market: Distribution by Geography, 2018-2030 (By Value)
    • 14.4.1. Drug Adherence Enhancement Market in North America, 2018-2030 (By Value)
    • 14.4.2. Drug Adherence Enhancement Market in Europe, 2018-2030 (By Value)
    • 14.4.3. Drug Adherence Enhancement Market in Asia-Pacific, 2018-2030 (By Value)
    • 14.4.4. Drug Adherence Enhancement Market in Rest of the World, 2018-2030 (By Value)
  • 14.5. Global Drug Adherence Enhancement Market: Distribution by Type of Product and Geography (By Value)
    • 14.5.1. Drug Adherence Enhancement Market for Smart Inhalers, 2018-2030 (By Value)
      • 14.5.1.1. Drug Adherence Enhancement Market for Smart Inhalers in North America, 2018-2030 (By Value)
      • 14.5.1.2. Drug Adherence Enhancement Market for Smart Inhalers in Europe, 2018-2030 (By Value)
      • 14.5.1.3. Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, 2018-2030 (By Value)
      • 14.5.1.4. Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, 2018-2030 (By Value)
    • 14.5.2. Drug Adherence Enhancement Market for Smart Injectors, 2018-2030 (By Value)
      • 14.5.2.1. Drug Adherence Enhancement Market for Smart Injectors in North America, 2018-2030 (By Value)
      • 14.5.2.2. Drug Adherence Enhancement Market for Smart Injectors in Europe, 2018-2030 (By Value)
      • 14.5.2.3. Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, 2018-2030 (By Value)
      • 14.5.2.4. Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, 2018-2030 (By Value)
    • 14.5.3. Drug Adherence Enhancement Market for Smart Wearable Injectors, 2018-2030 (By Value)
      • 14.5.3.1. Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, 2018-2030 (By Value)
      • 14.5.3.2. Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, 2018-2030 (By Value)
      • 14.5.3.3. Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, 2018-2030 (By Value)
      • 14.5.3.4. Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, 2018-2030 (By Value)
    • 14.5.4. Drug Adherence Enhancement Market for Smart Pills, 2018-2030 (By Value)
      • 14.5.4.1. Drug Adherence Enhancement Market for Smart Pills in North America, 2018-2030 (By Value)
      • 14.5.4.2. Drug Adherence Enhancement Market for Smart Pills in Europe, 2018-2030 (By Value)
      • 14.5.4.3. Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, 2018-2030 (By Value)
      • 14.5.4.4. Drug Adherence Enhancement Market for Smart Pills in Rest of the World, 2018-2030 (By Value)
    • 14.5.5. Drug Adherence Enhancement Market for Smart Medication Dispensers, 2018-2030 (By Value)
      • 14.5.5.1. Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, 2018-2030 (By Value)
      • 14.5.5.2. Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, 2018-2030 (By Value)
      • 14.5.5.3. Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, 2018-2030 (By Value)
      • 14.5.5.4. Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, 2018-2030 (By Value)
    • 14.5.6. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, 2018-2030 (By Value)
      • 14.5.6.1. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, 2018-2030 (By Value)
      • 14.5.6.2. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, 2018-2030 (By Value)
      • 14.5.6.3. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, 2018-2030 (By Value)
      • 14.5.6.4. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, 2018-2030 (By Value)
    • 14.5.7. Drug Adherence Enhancement Market for Smart Blister Packs, 2018-2030 (By Value)
      • 14.5.7.1. Drug Adherence Enhancement Market for Smart Blister Packs in North America, 2018-2030 (By Value)
      • 14.5.7.2. Drug Adherence Enhancement Market for Smart Blister Packs in Europe, 2018-2030 (By Value)
      • 14.5.7.3. Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, 2018-2030 (By Value)
      • 14.5.7.4. Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, 2018-2030 (By Value)
    • 14.5.8. Drug Adherence Enhancement Market for Other Type of Products, 2018-2030 (By Value)
      • 14.5.8.1. Drug Adherence Enhancement Market for Other Type of Products in North America, 2018-2030 (By Value)
      • 14.5.8.2. Drug Adherence Enhancement Market for Other Type of Products in Europe, 2018-2030 (By Value)
      • 14.5.8.3. Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, 2018-2030 (By Value)
      • 14.5.8.4. Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, 2018-2030 (By Value)
  • 14.6. Global Drug Adherence Enhancement Market: Distribution by Type of Product (By Volume)
    • 14.6.1. Drug Adherence Enhancement Market for Smart Inhalers, 2018-2030 (By Volume)
      • 14.6.1.1. Drug Adherence Enhancement Market for Smart Inhalers in North America, 2018-2030 (By Volume)
      • 14.6.1.2. Drug Adherence Enhancement Market for Smart Inhalers in Europe, 2018-2030 (By Volume)
      • 14.6.1.3. Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, 2018-2030 (By Volume)
      • 14.6.1.4. Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, 2018-2030 (By Volume)
    • 14.6.2. Drug Adherence Enhancement Market for Smart Injectors, 2018-2030 (By Volume)
      • 14.6.2.1. Drug Adherence Enhancement Market for Smart Injectors in North America, 2018-2030 (By Volume)
      • 14.6.2.2. Drug Adherence Enhancement Market for Smart Injectors in Europe, 2018-2030 (By Volume)
      • 14.6.2.3. Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, 2018-2030 (By Volume)
      • 14.6.2.4. Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, 2018-2030 (By Volume)
    • 14.6.3. Drug Adherence Enhancement Market for Smart Wearable Injectors, 2018-2030 (By Volume)
      • 14.6.3.1. Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, 2018-2030 (By Volume)
      • 14.6.3.2. Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, 2018-2030 (By Volume)
      • 14.6.3.3. Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, 2018-2030 (By Volume)
      • 14.6.3.4. Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, 2018-2030 (By Volume)
    • 14.6.4. Drug Adherence Enhancement Market for Smart Pills, 2018-2030 (By Volume)
      • 14.6.4.1. Drug Adherence Enhancement Market for Smart Pills in North America, 2018-2030 (By Volume)
      • 14.6.4.2. Drug Adherence Enhancement Market for Smart Pills in Europe, 2018-2030 (By Volume)
      • 14.6.4.3. Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, 2018-2030 (By Volume)
      • 14.6.4.4. Drug Adherence Enhancement Market for Smart Pills in Rest of the World, 2018-2030 (By Volume)
    • 14.6.5. Drug Adherence Enhancement Market for Smart Medication Dispensers, 2018-2030 (By Volume)
      • 14.6.5.1. Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, 2018-2030 (By Volume)
      • 14.6.5.2. Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, 2018-2030 (By Volume)
      • 14.6.5.3. Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, 2018-2030 (By Volume)
      • 14.6.5.4. Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, 2018-2030 (By Volume)
    • 14.6.6. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, 2018-2030 (By Volume)
      • 14.6.6.1. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, 2018-2030 (By Volume)
      • 14.6.6.2. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, 2018-2030 (By Volume)
      • 14.6.6.3. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, 2018-2030 (By Volume)
      • 14.6.6.4. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, 2018-2030 (By Volume)
    • 14.6.7. Drug Adherence Enhancement Market for Smart Blister Packs, 2018-2030 (By Volume)
      • 14.6.7.1. Drug Adherence Enhancement Market for Smart Blister Packs in North America, 2018-2030 (By Volume)
      • 14.6.7.2. Drug Adherence Enhancement Market for Smart Blister Packs in Europe, 2018-2030 (By Volume)
      • 14.6.7.3. Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, 2018-2030 (By Volume)
      • 14.6.7.4. Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, 2018-2030 (By Volume)
    • 14.6.8. Drug Adherence Enhancement Market for Other Type of Products, 2018-2030 (By Volume)
      • 14.6.8.1. Drug Adherence Enhancement Market for Other Type of Products in North America, 2018-2030 (By Volume)
      • 14.6.8.2. Drug Adherence Enhancement Market for Other Type of Products in Europe, 2018-2030 (By Volume)
      • 14.6.8.3. Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, 2018-2030 (By Volume)
      • 14.6.8.4. Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, 2018-2030 (By Volume)
  • 14.7. Global Drug Adherence Enhancement Market: Distribution by Therapeutic Area and Geography (By Value)
    • 14.7.1. Drug Adherence Enhancement Market for Metabolic Disorders (By Value)
      • 14.7.1.1. Drug Adherence Enhancement Market for Metabolic Disorders in North America, 2018-2030 (By Value)
      • 14.7.1.2. Drug Adherence Enhancement Market for Metabolic Disorders in Europe, 2018-2030 (By Value)
      • 14.7.1.3. Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, 2018-2030 (By Value)
      • 14.7.1.4. Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, 2018-2030 (By Value)
    • 14.7.2. Drug Adherence Enhancement Market for Cardiovascular Disorders (By Value)
      • 14.7.2.1. Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, 2018-2030 (By Value)
      • 14.7.2.2. Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, 2018-2030 (By Value)
      • 14.7.2.3. Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030 (By Value)
      • 14.7.2.4. Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, 2018-2030 (By Value)
    • 14.7.3. Drug Adherence Enhancement Market for Respiratory Disorders (By Value)
      • 14.7.3.1. Drug Adherence Enhancement Market for Respiratory Disorders in North America, 2018-2030 (By Value)
      • 14.7.3.2. Drug Adherence Enhancement Market for Respiratory Disorders in Europe, 2018-2030 (By Value)
      • 14.7.3.3. Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, 2018-2030 (By Value)
      • 14.7.3.4. Drug Adherence Enhancement Market for Respiratory Disorders in Rest of The World, 2018-2030 (By Value)
    • 14.7.4. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders (By Value)
      • 14.7.4.1. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, 2018-2030 (By Value)
      • 14.7.4.2. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, 2018-2030 (By Value)
      • 14.7.4.3. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, 2018-2030 (By Value)
      • 14.7.4.4. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, 2018-2030 (By Value)
    • 14.7.5. Drug Adherence Enhancement Market for Other Disorders (By Value)
      • 14.7.5.1. Drug Adherence Enhancement Market for Other Disorders in North America, 2018-2030 (By Value)
      • 14.7.5.2. Drug Adherence Enhancement Market for Other Disorders in Europe, 2018-2030 (By Value)
      • 14.7.5.3. Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, 2018-2030 (By Value)
      • 14.7.5.4. Drug Adherence Enhancement Market for Other Disorders in Rest of the World, 2018-2030 (By Value)
  • 14.8. Global Drug Adherence Enhancement Market: Distribution by Therapeutic Area and Geography (By Volume)
    • 14.8.1. Drug Adherence Enhancement Market for Metabolic Disorders (By Volume)
      • 14.8.1.1. Drug Adherence Enhancement Market for Metabolic Disorders in North America, 2018-2030 (By Volume)
      • 14.8.1.2. Drug Adherence Enhancement Market for Metabolic Disorders in Europe, 2018-2030 (By Volume)
      • 14.8.1.3. Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, 2018-2030 (By Volume)
      • 14.8.1.4. Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, 2018-2030 (By Volume)
    • 14.8.2. Drug Adherence Enhancement Market for Cardiovascular Disorders (By Volume)
      • 14.8.2.1. Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, 2018-2030 (By Volume)
      • 14.8.2.2. Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, 2018-2030 (By Volume)
      • 14.8.2.3. Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030 (By Volume)
      • 14.8.2.4. Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, 2018-2030 (By Volume)
    • 14.8.3. Drug Adherence Enhancement Market for Respiratory Disorders (By Volume)
      • 14.8.3.1. Drug Adherence Enhancement Market for Respiratory Disorders in North America, 2018-2030 (By Volume)
      • 14.8.3.2. Drug Adherence Enhancement Market for Respiratory Disorders in Europe, 2018-2030 (By Volume)
      • 14.8.3.3. Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, 2018-2030 (By Volume)
      • 14.8.3.4. Drug Adherence Enhancement Market for Respiratory Disorders in Rest of The World, 2018-2030 (By Volume)
    • 14.8.4. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders (By Volume)
      • 14.8.4.1. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, 2018-2030 (By Volume)
      • 14.8.4.2. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, 2018-2030 (By Volume)
      • 14.8.4.3. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, 2018-2030 (By Volume)
      • 14.8.4.4. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, 2018-2030 (By Volume)
    • 14.8.5. Drug Adherence Enhancement Market for Other Disorders (By Volume)
      • 14.8.5.1. Drug Adherence Enhancement Market for Other Disorders in North America, 2018-2030 (By Volume)
      • 14.8.5.2. Drug Adherence Enhancement Market for Other Disorders in Europe, 2018-2030 (By Volume)
      • 14.8.5.3. Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, 2018-2030 (By Volume)
      • 14.8.5.4. Drug Adherence Enhancement Market for Other Disorders in Rest of the World, 2018-2030 (By Volume)
  • 14.9. Global Drug Adherence Enhancement Market: Distribution by Route of Drug Administration and Geography (By Value)
    • 14.9.1. Drug Adherence Enhancement Market for Products Intended for Oral Medications, 2018-2030 (By Value)
      • 14.9.1.1. Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, 2018-2030 (By Value)
      • 14.9.1.2. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, 2018-2030 (By Value)
      • 14.9.1.3. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, 2018-2030 (By Value)
      • 14.9.1.4. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, 2018-2030 (By Value)
    • 14.9.2. Drug Adherence Enhancement Market for Products Intended for Injectables, 2018-2030 (By Value)
      • 14.9.2.1. Drug Adherence Enhancement Market for Products Intended for Injectables in North America, 2018-2030 (By Value)
      • 14.9.2.2. Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, 2018-2030 (By Value)
      • 14.9.2.3. Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, 2018-2030 (By Value)
      • 14.9.2.4. Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, 2018-2030 (By Value)
    • 14.9.3. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, 2018-2030 (By Value)
      • 14.9.3.1. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, 2018-2030 (By Value)
      • 14.9.3.2. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, 2018-2030 (By Value)
      • 14.9.3.3. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, 2018-2030 (By Value)
      • 14.9.3.4. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, 2018-2030 (By Value)
    • 14.9.4. Drug Adherence Enhancement Market for Products Intended for Other Medications, 2018-2030 (By Value)
      • 14.9.4.1. Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, 2018-2030 (By Value)
      • 14.9.4.2. Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, 2018-2030 (By Value)
      • 14.9.4.3. Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, 2018-2030 (By Value)
      • 14.9.4.4. Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, 2018-2030 (By Value)
  • 14.10. Global Drug Adherence Enhancement Market: Distribution by Route of Drug Administration and Geography (By Volume)
    • 14.10.1. Drug Adherence Enhancement Market for Products Intended for Oral Medications, 2018-2030 (By Volume)
      • 14.10.1.1. Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, 2018-2030 (By Volume)
      • 14.10.1.2. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, 2018-2030 (By Volume)
      • 14.10.1.3. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, 2018-2030 (By Volume)
      • 14.10.1.4. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, 2018-2030 (By Volume)
    • 14.10.2. Drug Adherence Enhancement Market for Products Intended for Injectables, 2018-2030 (By Volume)
      • 14.10.2.1. Drug Adherence Enhancement Market for Products Intended for Injectables in North America, 2018-2030 (By Volume)
      • 14.10.2.2. Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, 2018-2030 (By Volume)
      • 14.10.2.3. Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, 2018-2030 (By Volume)
      • 14.10.2.4. Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, 2018-2030 (By Volume)
    • 14.10.3. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, 2018-2030 (By Volume)
      • 14.10.3.1. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, 2018-2030 (By Volume)
      • 14.10.3.2. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, 2018-2030 (By Volume)
      • 14.10.3.3. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, 2018-2030 (By Volume)
      • 14.10.3.4. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, 2018-2030 (By Volume)
    • 14.10.4. Drug Adherence Enhancement Market for Products Intended for Other Medications, 2018-2030 (By Volume)
      • 14.10.4.1. Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, 2018-2030 (By Volume)
      • 14.10.4.2. Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, 2018-2030 (By Volume)
      • 14.10.4.3. Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, 2018-2030 (By Volume)
      • 14.10.4.4. Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, 2018-2030 (By Volume)

15. CONCLUSION

  • 15.1. Poor Adherence to Therapies for the Treatment of Chronic Disorders Poses a Significant Economic Burden on the Healthcare Industry
  • 15.2. Presently, Several Players are Developing IoT-Enabled / Connected Devices for Improving Medication Adherence; Majority of these are Small-sized Companies based in the US
  • 15.3. Increasing Financial Support from Various Investors is Indicative of Future Opportunities related to Novel Strategies for Medication Adherence Improvement
  • 15.4. Players have Entered into Strategic Collaborations to Support the Development of their Smart Products
  • 15.5. Availability of Standalone, as well as Companion Mobile Applications, is Expected to Provide a More Integrated Approach for Improving Adherence
  • 15.6. With Increasing Focus on Improving Therapy Efficacy and Alleviating Healthcare Burden, the Overall Market is Anticipated to Witness Steady Growth

16. EXECUTIVE INSIGHTS

  • 16.1. Chapter Overview
  • 16.2. AARDEX Group
    • 16.2.1. Company Snapshot
    • 16.2.2. Interview Transcript: Bernard Vrijens, Chief Executive Officer
  • 16.3. AceAge
    • 16.3.1. Company Snapshot
    • 16.3.2. Interview Transcript: Spencer Waugh, Chief Executive Officer
  • 16.4. AdhereTech
    • 16.4.1. Company Snapshot
    • 16.4.2. Interview Transcript: Josh Stein, Chief Executive Officer
  • 16.5. Amiko Digital Health
    • 16.5.1. Company Snapshot
    • 16.5.2. Interview Transcript: Duilio Macchi, Chief Executive Officer
  • 16.6. Cognita Labs
    • 16.6.1. Company Snapshot
    • 16.6.2. Interview Transcript: Gaurav Patel, Chief Technical Officer
  • 16.7. etectRx
    • 16.7.1. Company Snapshot
    • 16.7.2. Interview Transcript: Tina Valbh, Strategy and Business Development (Advisor)
  • 16.8. PharmAdva
    • 16.8.1. Company Snapshot
    • 16.8.2. Interview Transcript: Jonathan Sacks, Chief Executive Officer and Chairman
  • 16.9. Popit Technologies
    • 16.9.1. Company Snapshot
    • 16.9.2. Interview Transcript: Timo Heikkilä, Co-Founder and Chief Operating Officer
  • 16.10. Wealth Taxi
    • 16.10.1. Company Snapshot
    • 16.10.2. Interview Transcript: Moore Greenberg, Founder
  • 16.11 Small-sized Company
    • 16.11.1 Interview Transcript: Anonymous

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures:

  • Figure 3.1: Types of Medication Non-Adherence
  • Figure 3.2: Factors Contributing to Non-Adherence
  • Figure 3.3: Framework of IoT Assisted Adherence Platform
  • Figure 4.1: Smart Drug Delivery Devices: Distribution of Developers by Year of Establishment
  • Figure 4.2: Smart Drug Delivery Devices: Distribution of Developers by Geographical Location (Region-wise)
  • Figure 4.3: Smart Drug Delivery Devices: Distribution of Developers by Geographical Location (Country-wise)
  • Figure 4.4: Smart Drug Delivery Devices: Distribution of Developers by Size (Employee Count)
  • Figure 4.5: Smart Drug Delivery Devices: Distribution by Type of Device
  • Figure 4.6: Smart Drug Delivery Devices: Distribution by Mode of Drug Delivery
  • Figure 4.7: Smart Drug Delivery Devices: Distribution by Key Specifications
  • Figure 4.8: Smart Drug Delivery Devices: Distribution by Availability of Audio / Visual Reminders
  • Figure 4.9: Smart Drug Delivery Devices: Distribution by Availability of Connectivity (USB, Bluetooth, or Cellular)
  • Figure 4.10: Smart Drug Delivery Devices: Distribution by Availability of Companion Mobile Application
  • Figure 4.11: Smart Drug Delivery Devices: Distribution by Availability of Companion Web Portal
  • Figure 4.12: Smart Drug Delivery Devices: Distribution by Availability of Data Storage / Cloud Platform
  • Figure 4.13: Smart Drug Delivery Devices: Distribution by Battery Backup / Rechargeable Battery
  • Figure 4.14: Smart Drug Delivery Devices: Key Players
  • Figure 4.15: Smart Inhalers: Distribution of Developers by Year of Establishment
  • Figure 4.16: Smart Inhalers: Distribution of Developers by Geographical Location
  • Figure 4.17: Smart Inhalers: Distribution of Developers by Size (Employee Count)
  • Figure 4.18: Smart Inhalers: Distribution by Key Device Specifications
  • Figure 4.19: Smart Injectors: Distribution of Developers by Year of Establishment
  • Figure 4.20: Smart Injectors: Distribution of Developers by Geographical Location
  • Figure 4.21: Smart Injectors: Distribution of Developers by Size (Employee Count)
  • Figure 4.22: Smart Injectors: Distribution by Key Device Specifications
  • Figure 4.23: Smart Wearable Injectors: Distribution of Developers by Year of Establishment
  • Figure 4.24: Smart Wearable Injectors: Distribution of Developers by Geographical Location
  • Figure 4.25: Smart Wearable Injectors: Distribution of Developers by Size (Employee Count)
  • Figure 4.26: Smart Wearable Injectors: Distribution by Key Device Specifications
  • Figure 4.27: Smart Pills / Other Smart Devices: Distribution of Developers by Year of Establishment
  • Figure 4.28: Smart Pills / Other Smart Devices: Distribution of Developers by Geographical Location
  • Figure 4.29: Smart Pills / Other Smart Devices: Distribution of Developers by Size (Employee Count)
  • Figure 4.30: Smart Pills / Other Smart Devices: Distribution by Key Device Specifications
  • Figure 5.1: Smart Accessory Devices: Distribution of Developers by Year of Establishment
  • Figure 5.2: Smart Accessory Devices: Distribution of Developers by Geographical Location (Region-wise)
  • Figure 5.3: Smart Accessory Devices: Distribution of Developers by Geographical Location (Country-wise)
  • Figure 5.4: Smart Accessory Devices: Distribution of Developers by Size (Employee Count)
  • Figure 5.5: Smart Accessory Devices: Distribution by Type of Device
  • Figure 5.6: Smart Accessory Devices: Distribution by Key Specifications
  • Figure 5.7: Smart Accessory Devices: Distribution by Availability of Audio / Visual Reminders
  • Figure 5.8: Smart Accessory Devices: Distribution by Availability of Connectivity (USB, Bluetooth, Wi-Fi, or Cellular)
  • Figure 5.9: Smart Accessory Devices: Distribution by Availability of Companion Mobile Application
  • Figure 5.10: Smart Accessory Devices: Distribution by Availability of Companion Web Portal
  • Figure 5.11: Smart Accessory Devices: Distribution by Availability of Data Storage / Cloud Platform
  • Figure 5.12: Smart Accessory Devices: Distribution by Availability of Battery Backup / Rechargeable
  • Figure 5.13: Smart Accessory Devices: Key Players
  • Figure 5.14: Smart Medication Dispensers: Distribution of Developers by Year of Establishment
  • Figure 5.15: Smart Medication Dispensers: Distribution of Developers by Geographical Location
  • Figure 5.16: Smart Medication Dispensers: Distribution of Developers by Size (Employee Count)
  • Figure 5.17: Smart Medication Dispensers: Distribution by Key Device Specifications
  • Figure 5.18: Smart Pill Bottles / Caps: Distribution of Developers by Year of Establishment
  • Figure 5.19: Smart Pill Bottles / Caps: Distribution of Developers by Geographical Location
  • Figure 5.20: Smart Pill Bottles / Caps: Distribution of Developers by Size (Employee Count)
  • Figure 5.21: Smart Pill Bottles / Caps: Distribution by Key Device Specifications
  • Figure 5.22: Smart Pill Boxes: Distribution of Developers by Year of Establishment
  • Figure 5.23: Smart Pill Boxes: Distribution of Developers by Geographical Location
  • Figure 5.24: Smart Pill Boxes: Distribution of Developers by Size (Employee Count)
  • Figure 5.25: Smart Pill Boxes: Distribution by Key Device Specifications
  • Figure 5.26: Smart Blister Packs: Distribution of Developers by Year of Establishment
  • Figure 5.27: Smart Blister Packs: Distribution of Developers by Geographical Location
  • Figure 5.28: Smart Blister Packs: Distribution of Developers by Size (Employee Count)
  • Figure 5.29: Smart Blister Packs: Distribution by Key Device Specifications
  • Figure 5.30: Other Smart Devices: Distribution of Developers by Year of Establishment
  • Figure 5.31: Other Smart Devices: Distribution of Developers by Geographical Location
  • Figure 5.32: Other Smart Devices: Distribution of Developers by Size (Employee Count)
  • Figure 5.33: Other Smart Devices: Distribution by Key Device Specifications
  • Figure 5.34: Compliance Packaging Systems: Distribution of Developers by Geographical Location
  • Figure 5.35: Compliance Packaging Systems: Distribution of Developers by Size (Employee Count)
  • Figure 5.36: Compliance Packaging Systems: Distribution by Type of Packaging System
  • Figure 5.37: Compliance Packaging Systems: Distribution by Number of Doses per Pack
  • Figure 5.38: Compliance Packaging Systems: Distribution by Availability of Other Features
  • Figure 6.1: Global Regulations Related to Smart Inhalers, Smart Injectors and Smart Wearable Injectors
  • Figure 6.2: USFDA: Approval Pathway for Combination Products
  • Figure 6.3: Health Canada: Approval Pathway for Combination Products
  • Figure 6.4: CFDA: Approval Pathway of Combination Products
  • Figure 7.1: Adherium: Annual Revenues, FY 2015-H1 FY 2018 (USD Million)
  • Figure 7.2: Adherium: Working Mechanism of Hailie™
  • Figure 7.3: BIOCORP: Annual Revenues, 2014-2017 (EUR Million)
  • Figure 7.4: nGageIT Digital Health: Data Points Captured by Nanoparticle Sensor
  • Figure 7.5: nGageIT Digital Health: Key Features of nGageIT Injectable Sensor Technologies
  • Figure 7.6: Proteus Digital Health: Major Components of Proteus Discover
  • Figure 7.7: Ypsomed: Annual Revenues, FY2013 - FY2017 (CHF Million)
  • Figure 7.8: Ypsomed: Sales by Business Divisions, FY2017 (CHF Million)
  • Figure 7.9: Ypsomed: Features of YpsoMate® SmartPilot
  • Figure 7.10: Ypsomed: Components of mylife Ypsopump
  • Figure 8.1: MedMinder Systems: Key Features of Pill Dispensers
  • Figure 8.2: MedMinder Systems: Key Differences of Pill Dispensers
  • Figure 8.3: Philips: Annual Revenues, 2013- H1 2018 (EUR Billion)
  • Figure 8.4: Philips: Revenues by Business Segments, H1 2018 (EUR Billion)
  • Figure 8.5: Philips: Key Features of spencer®
  • Figure 8.6: Tinylogics: Key Features of Memo Box
  • Figure 8.7: Vaica: Complete Range of Solutions
  • Figure 8.8: Vaica: Study Results
  • Figure 9.1: Diabetes: Global Prevalence
  • Figure 9.2: Diabetes: Evolution of Drug Delivery / Connected Devices
  • Figure 9.3: Impact of Drug Delivery / Connected Devices in Improving Drug Adherence in Diabetic Patients: Highlights on Twitter
  • Figure 9.4: Asthma: Global Prevalence
  • Figure 9.5: Asthma: Evolution of Drug Delivery / Connected Devices
  • Figure 9.6: Smart Inhalers / Connected Devices: Potential Applications
  • Figure 9.10: Impact of Drug Delivery / Connected Devices in Improving Drug Adherence in Asthma Patients: Highlights on Twitter
  • Figure 9.11: Rheumatoid Arthritis: Global Prevalence
  • Figure 9.12: Rheumatoid Arthritis: Evolution of Drug Delivery / Connected Devices
  • Figure 9.13: Impact of Drug Delivery / Connected Devices in Improving Drug Adherence in Rheumatoid Arthritis Patients: Highlights on Twitter
  • Figure 10.1: Overall Product Competitiveness Analysis
  • Figure 10.2: Overall Product Competitiveness Analysis: Distribution of Different Types of Products by Scores
  • Figure 10.3: Product Competitiveness Analysis: Smart Medication Dispensers
  • Figure 10.4: Product Competitiveness Analysis: Smart Pill Packaging Systems
  • Figure 10.5: Product Competitiveness Analysis: Smart Inhalers
  • Figure 10.6: Product Competitiveness Analysis: Smart Injectors
  • Figure 10.7: Product Competitiveness Analysis: Smart Wearable Injectors
  • Figure 11.1: Funding and Investment Analysis: Cumulative Number of Instances, January 2001-August 2018
  • Figure 11.2: Funding and Investment Analysis: Cumulative Amount Invested, January 2001-August 2018 (USD Million)
  • Figure 11.3: Funding and Investment Analysis: Distribution by Type of Funding, January 2001-August 2018
  • Figure 11.4: Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, January 2001-August 2018 (USD Million)
  • Figure 11.5: Funding and Investment Analysis: Summary of Investments, January 2001-August 2018 (USD Million)
  • Figure 11.6: Funding and Investment Analysis: Distribution of Number of Funding Instances by Year of Investment and Major Device Categories, January 2001-August 2018
  • Figure 11.7: Funding and Investment Analysis: Distribution of Number of Funding Instances by Type of Funding and Major Device Categories, January 2001-August 2018
  • Figure 11.8: Funding and Investment Analysis: Distribution of Amount Invested by Year of Investment and Major Device Categories, January 2001-August 2018
  • Figure 11.9: Funding and Investment Analysis: Most Active Players in terms of Number of Instances, January 2001-August 2018
  • Figure 11.10: Funding and Investment Analysis: Most Active Players in terms of Amount Raised (USD Million), January 2001-August 2018
  • Figure 11.12: Funding and Investment Analysis: Most Active Investors
  • Figure 11.13: Funding and Investment Summary
  • Figure 12.1: Partnerships and Collaborations: Distribution by Year, 2010-2018
  • Figure 12.2: Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 12.3: Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 12.4: Partnerships and Collaborations: Most Active Players
  • Figure 12.5: Partnerships and Collaborations: Distribution by Type and Year of Partnership
  • Figure 12.6: Partnerships and Collaborations: Distribution by Type of Partnership and Geographical Presence of Companies
  • Figure 12.7: Partnerships and Collaborations: Regional Distribution
  • Figure 13.1: Clinical Trial Publications for Improving Medication Adherence through Software Applications: Distribution by Therapeutic Areas
  • Figure 14.1: Global Drug Adherence Enhancement Market, 2018-2030 (USD Billion)
  • Figure 14.2: Drug Adherence Enhancement Market for Smart Drug Delivery Devices, 2018-2030 (USD Billion)
  • Figure 14.3: Drug Adherence Enhancement Market for Smart Accessory Devices, 2018-2030 (USD Billion)
  • Figure 14.4: Drug Adherence Enhancement Market for Other Type of Devices, 2018-2030 (USD Billion)
  • Figure 14.5: Global Drug Adherence Enhancement Market, 2018-2030 (Units, Million)
  • Figure 14.6: Drug Adherence Enhancement Market for Smart Drug Delivery Devices, 2018-2030 (Units, Million)
  • Figure 14.7: Drug Adherence Enhancement Market for Smart Accessory Devices, 2018-2030 (Units, Million)
  • Figure 14.8: Drug Adherence Enhancement Market for Other Type of Devices, 2018-2030 (Units, Million)
  • Figure 14.9: Drug Adherence Enhancement Market in North America, 2018-2030 (USD Billion)
  • Figure 14.10: Drug Adherence Enhancement Market in Europe, 2018-2030 (USD Billion)
  • Figure 14.11: Drug Adherence Enhancement Market in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.12: Drug Adherence Enhancement Market in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.13: Drug Adherence Enhancement Market for Smart Inhalers, 2018-2030 (USD Billion)
  • Figure 14.14: Drug Adherence Enhancement Market for Smart Inhalers in North America, 2018-2030 (USD Billion)
  • Figure 14.15: Drug Adherence Enhancement Market for Smart Inhalers in Europe, 2018-2030 (USD Billion)
  • Figure 14.16: Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.17: Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.18: Drug Adherence Enhancement Market for Smart Injectors, 2018-2030 (USD Billion)
  • Figure 14.19: Drug Adherence Enhancement Market for Smart Injectors in North America, 2018-2030 (USD Billion)
  • Figure 14.20: Drug Adherence Enhancement Market for Smart Injectors in Europe, 2018-2030 (USD Billion)
  • Figure 14.21: Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.22: Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.23: Drug Adherence Enhancement Market for Smart Wearable Injectors, 2018-2030 (USD Billion)
  • Figure 14.24: Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, 2018-2030 (USD Billion)
  • Figure 14.25: Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, 2018-2030 (USD Billion)
  • Figure 14.26: Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.27: Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.28: Drug Adherence Enhancement Market for Smart Pills, 2018-2030 (USD Billion)
  • Figure 14.29: Drug Adherence Enhancement Market for Smart Pills in North America, 2018-2030 (USD Billion)
  • Figure 14.30: Drug Adherence Enhancement Market for Smart Pills in Europe, 2018-2030 (USD Billion)
  • Figure 14.31: Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.32: Drug Adherence Enhancement Market for Smart Pills in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.33: Drug Adherence Enhancement Market for Smart Medication Dispensers, 2018-2030 (USD Billion)
  • Figure 14.34: Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, 2018-2030 (USD Billion)
  • Figure 14.35: Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, 2018-2030 (USD Billion)
  • Figure 14.36: Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.37: Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.38: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, 2018-2030 (USD Billion)
  • Figure 14.39: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, 2018-2030 (USD Billion)
  • Figure 14.40: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, 2018-2030 (USD Billion)
  • Figure 14.41: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.42: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.43: Drug Adherence Enhancement Market for Smart Blister Packs, 2018-2030 (USD Billion)
  • Figure 14.44: Drug Adherence Enhancement Market for Smart Blister Packs in North America, 2018-2030 (USD Billion)
  • Figure 14.45: Drug Adherence Enhancement Market for Smart Blister Packs in Europe, 2018-2030 (USD Billion)
  • Figure 14.46: Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.47: Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.48: Drug Adherence Enhancement Market for Other Type of Products, 2018-2030 (USD Billion)
  • Figure 14.49: Drug Adherence Enhancement Market for Other Type of Products in North America, 2018-2030 (USD Billion)
  • Figure 14.50: Drug Adherence Enhancement Market for Other Type of Products in Europe, 2018-2030 (USD Billion)
  • Figure 14.51: Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.52: Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.53: Drug Adherence Enhancement Market for Smart Inhalers, 2018-2030 (Units, Million)
  • Figure 14.54: Drug Adherence Enhancement Market for Smart Inhalers in North America, 2018-2030 (Units, Million)
  • Figure 14.55: Drug Adherence Enhancement Market for Smart Inhalers in Europe, 2018-2030 (Units, Million)
  • Figure 14.56: Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, 2018-2030 (Units, Million)
  • Figure 14.57: Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, 2018-2030 (Units, Million)
  • Figure 14.58: Drug Adherence Enhancement Market for Smart Injectors, 2018-2030 (Units, Million)
  • Figure 14.59: Drug Adherence Enhancement Market for Smart Injectors in North America, 2018-2030 (Units, Million)
  • Figure 14.60: Drug Adherence Enhancement Market for Smart Injectors in Europe, 2018-2030 (Units, Million)
  • Figure 14.61: Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, 2018-2030 (Units, Million)
  • Figure 14.62: Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, 2018-2030 (Units, Million)
  • Figure 14.63: Drug Adherence Enhancement Market for Smart Wearable Injectors, 2018-2030 (Units, Million)
  • Figure 14.64: Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, 2018-2030 (Units, Million)
  • Figure 14.65: Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, 2018-2030 (Units, Million)
  • Figure 14.66: Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, 2018-2030 (Units, Million)
  • Figure 14.67: Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, 2018-2030 (Units, Million)
  • Figure 14.68: Drug Adherence Enhancement Market for Smart Pills, 2018-2030 (Units, Million)
  • Figure 14.69: Drug Adherence Enhancement Market for Smart Pills in North America, 2018-2030 (Units, Million)
  • Figure 14.70: Drug Adherence Enhancement Market for Smart Pills in Europe, 2018-2030 (Units, Million)
  • Figure 14.71: Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, 2018-2030 (Units, Million)
  • Figure 14.72: Drug Adherence Enhancement Market for Smart Pills in Rest of the World, 2018-2030 (Units, Million)
  • Figure 14.73: Drug Adherence Enhancement Market for Smart Medication Dispensers, 2018-2030 (Units, Million)
  • Figure 14.74: Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, 2018-2030 (Units, Million)
  • Figure 14.75: Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, 2018-2030 (Units, Million)
  • Figure 14.76: Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, 2018-2030 (Units, Million)
  • Figure 14.77: Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, 2018-2030 (Units, Million)
  • Figure 14.78: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, 2018-2030 (Units, Million)
  • Figure 14.79: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, 2018-2030 (Units, Million)
  • Figure 14.80: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, 2018-2030 (Units, Million)
  • Figure 14.81: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, 2018-2030 (Units, Million)
  • Figure 14.82: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, 2018-2030 (Units, Million)
  • Figure 14.83: Drug Adherence Enhancement Market for Smart Blister Packs, 2018-2030 (Units, Million)
  • Figure 14.84: Drug Adherence Enhancement Market for Smart Blister Packs in North America, 2018-2030 (Units, Million)
  • Figure 14.85: Drug Adherence Enhancement Market for Smart Blister Packs in Europe, 2018-2030 (Units, Million)
  • Figure 14.86: Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, 2018-2030 (Units, Million)
  • Figure 14.87: Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, 2018-2030 (Units, Million)
  • Figure 14.88: Drug Adherence Enhancement Market for Other Type of Products, 2018-2030 (Units, Million)
  • Figure 14.89: Drug Adherence Enhancement Market for Other Type of Products in North America, 2018-2030 (Units, Million)
  • Figure 14.90: Drug Adherence Enhancement Market for Other Type of Products in Europe, 2018-2030 (Units, Million)
  • Figure 14.91: Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, 2018-2030 (Units, Million)
  • Figure 14.92: Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, 2018-2030 (Units, Million)
  • Figure 14.93: Drug Adherence Enhancement Market for Metabolic Disorders, 2018-2030 (USD Billion)
  • Figure 14.94: Drug Adherence Enhancement Market for Metabolic Disorders in North America, 2018-2030 (USD Billion)
  • Figure 14.95: Drug Adherence Enhancement Market for Metabolic Disorders in Europe, 2018-2030 (USD Billion)
  • Figure 14.96: Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.97: Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.98: Drug Adherence Enhancement Market for Cardiovascular Disorders, 2018-2030 (USD Billion)
  • Figure 14.99: Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, 2018-2030 (USD Billion)
  • Figure 14.100: Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, 2018-2030 (USD Billion)
  • Figure 14.101: Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.102: Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.103: Drug Adherence Enhancement Market for Respiratory Disorders, 2018-2030 (USD Billion)
  • Figure 14.104: Drug Adherence Enhancement Market for Respiratory Disorders in North America, 2018-2030 (USD Billion)
  • Figure 14.105: Drug Adherence Enhancement Market for Respiratory Disorders in Europe, 2018-2030 (USD Billion)
  • Figure 14.106: Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.107: Drug Adherence Enhancement Market for Respiratory Disorders in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.108: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders, 2018-2030 (USD Billion)
  • Figure 14.109: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, 2018-2030 (USD Billion)
  • Figure 14.110: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, 2018-2030 (USD Billion)
  • Figure 14.111: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.112: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.113: Drug Adherence Enhancement Market for Other Disorders, 2018-2030 (USD Billion)
  • Figure 14.114: Drug Adherence Enhancement Market for Other Disorders in North America, 2018-2030 (USD Billion)
  • Figure 14.115: Drug Adherence Enhancement Market for Other Disorders in Europe, 2018-2030 (USD Billion)
  • Figure 14.116: Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.117: Drug Adherence Enhancement Market for Other Disorders in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.118: Drug Adherence Enhancement Market for Metabolic Disorders, 2018-2030 (Units, Million)
  • Figure 14.119: Drug Adherence Enhancement Market for Metabolic Disorders in North America, 2018-2030 (Units, Million)
  • Figure 14.120: Drug Adherence Enhancement Market for Metabolic Disorders in Europe, 2018-2030 (Units, Million)
  • Figure 14.121: Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, 2018-2030 (Units, Million)
  • Figure 14.122: Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, 2018-2030 (Units, Million)
  • Figure 14.123: Drug Adherence Enhancement Market for Cardiovascular Disorders, 2018-2030 (Units, Million)
  • Figure 14.124: Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, 2018-2030 (Units, Million)
  • Figure 14.125: Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, 2018-2030 (Units, Million)
  • Figure 14.126: Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030 (Units, Million)
  • Figure 14.127: Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, 2018-2030 (Units, Million)
  • Figure 14.128: Drug Adherence Enhancement Market for Respiratory Disorders, 2018-2030 (Units, Million)
  • Figure 14.129: Drug Adherence Enhancement Market for Respiratory Disorders in North America, 2018-2030 (Units, Million)
  • Figure 14.130: Drug Adherence Enhancement Market for Respiratory Disorders in Europe, 2018-2030 (Units, Million)
  • Figure 14.131: Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, 2018-2030 (Units, Million)
  • Figure 14.132: Drug Adherence Enhancement Market for Respiratory Disorders in Rest of the World, 2018-2030 (Units, Million)
  • Figure 14.133: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders, 2018-2030 (Units, Million)
  • Figure 14.134: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, 2018-2030 (Units, Million)
  • Figure 14.135: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, 2018-2030 (Units, Million)
  • Figure 14.136: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, 2018-2030 (Units, Million)
  • Figure 14.137: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, 2018-2030 (Units, Million)
  • Figure 14.138: Drug Adherence Enhancement Market for Other Disorders, 2018-2030 (Units, Million)
  • Figure 14.139: Drug Adherence Enhancement Market for Other Disorders in North America, 2018-2030 (Units, Million)
  • Figure 14.140: Drug Adherence Enhancement Market for Other Disorders in Europe, 2018-2030 (Units, Million)
  • Figure 14.141: Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, 2018-2030 (Units, Million)
  • Figure 14.142: Drug Adherence Enhancement Market for Other Disorders in Rest of the World, 2018-2030 (Units, Million)
  • Figure 14.143: Drug Adherence Enhancement Market for Products Intended for Oral Medications, 2018-2030 (USD Billion)
  • Figure 14.144: Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, 2018-2030 (USD Billion)
  • Figure 14.145: Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, 2018-2030 (USD Billion)
  • Figure 14.146: Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.147: Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.148: Drug Adherence Enhancement Market for Products Intended for Injectables, 2018-2030 (USD Billion)
  • Figure 14.149: Drug Adherence Enhancement Market for Products Intended for Injectables in North America, 2018-2030 (USD Billion)
  • Figure 14.150: Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, 2018-2030 (USD Billion)
  • Figure 14.151: Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.152: Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.153: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, 2018-2030 (USD Billion)
  • Figure 14.154: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, 2018-2030 (USD Billion)
  • Figure 14.155: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, 2018-2030 (USD Billion)
  • Figure 14.156: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.157: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.158: Drug Adherence Enhancement Market for Products Intended for Other Medications, 2018-2030 (USD Billion)
  • Figure 14.159: Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, 2018-2030 (USD Billion)
  • Figure 14.160: Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, 2018-2030 (USD Billion)
  • Figure 14.161: Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, 2018-2030 (USD Billion)
  • Figure 14.162: Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, 2018-2030 (USD Billion)
  • Figure 14.163: Drug Adherence Enhancement Market for Products Intended for Oral Medications, 2018-2030 (Units, Million)
  • Figure 14.164: Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, 2018-2030 (Units, Million)
  • Figure 14.165: Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, 2018-2030 (Units, Million)
  • Figure 14.166: Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, 2018-2030 (Units, Million)
  • Figure 14.167: Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, 2018-2030 (Units, Million)
  • Figure 14.168: Drug Adherence Enhancement Market for Products Intended for Injectables, 2018-2030 (Units, Million)
  • Figure 14.169: Drug Adherence Enhancement Market for Products Intended for Injectables in North America, 2018-2030 (Units, Million)
  • Figure 14.170: Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, 2018-2030 (Units, Million)
  • Figure 14.171: Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, 2018-2030 (Units, Million)
  • Figure 14.172: Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, 2018-2030 (Units, Million)
  • Figure 14.173: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, 2018-2030 (Units, Million)
  • Figure 14.174: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, 2018-2030 (Units, Million)
  • Figure 14.175: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, 2018-2030 (Units, Million)
  • Figure 14.176: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, 2018-2030 (Units, Million)
  • Figure 14.177: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, 2018-2030 (Units, Million)
  • Figure 14.178: Drug Adherence Enhancement Market for Products Intended for Other Medications, 2018-2030 (Units, Million)
  • Figure 14.179: Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, 2018-2030 (Units, Million)
  • Figure 14.180: Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, 2018-2030 (Units, Million)
  • Figure 14.181: Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, 2018-2030 (Units, Million)
  • Figure 14.182: Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, 2018-2030 (Units, Million)
  • Figure 15.1: Overall Drug Adherence Enhancement Market, Conservative, Base and Optimistic Scenarios, 2018 and 2030

List of Tables:

  • Table 3.1: Medication Adherence: Methods of Measurement
  • Table 3.2: Traditional Interventions for Improving Medication Adherence
  • Table 4.1: Smart Drug Delivery Devices: Information on Developers
  • Table 4.2: Smart Drug Delivery Devices: Information on Key Device Specifications
  • Table 5.1: Smart Accessory Devices: Information on Developers
  • Table 5.2: Smart Accessory Devices: Information on Key Device Specifications
  • Table 5.3: Compliance Packaging Systems: Information on Developers
  • Table 5.4: Compliance Packaging Systems: Information on Key Specifications
  • Table 6.1: USFDA Centers for Drugs and Device Approval
  • Table 6.2: USFDA: Review Timelines
  • Table 6.3: Regulatory Bodies in EU5 Countries
  • Table 6.4: SFDA: Regulatory Review Timeline
  • Table 7.1: Adherium: List of Medications Used with Hailie™ Sensors
  • Table 7.2: Adherium: Recent Developments and Future Outlook
  • Table 7.3: BIOCORP: Recent Developments and Future Outlook
  • Table 7.4: nGageIT Digital Health: Recent Developments and Future Outlook
  • Table 7.5: Proteus Digital Health: Recent Developments and Future Outlook
  • Table 7.6: SOOIL Development: Recent Developments and Future Outlook
  • Table 7.7: Ypsomed: Specifications of mylife™ YpsoPump®:
  • Table 7.8: Ypsomed: Recent Developments and Future Outlook
  • Table 8.1: AARDEX Group: Recent Developments and Future Outlook
  • Table 8.2: Information Mediary: Specifications of Med-ic® Electronic Compliance Monitor®
  • Table 8.3: Information Mediary: Specifications of eCap™ Electronic Compliance Monitor®
  • Table 8.4: Information Mediary: Specifications of Med-ic® Coolblue Syringe Pack
  • Table 8.5: Information Mediary: Specifications of CertiScan® Reader and Software
  • Table 8.6: Information Mediary: Areas of Application of Med-ic® Smart Label and eCap™
  • Table 8.7: Information Mediary: Recent Developments and Future Outlook
  • Table 8.8: MedMinder Systems: Recent Developments and Future Outlook
  • Table 8.9: Philips: Specifications of spencer®
  • Table 8.10: Philips: Key Features and Advantages of Philips Automated Medication Dispensing Services
  • Table 8.11: Philips: Recent Developments and Future Outlook
  • Table 8.12: Vaica: Specifications of SimpleMed+
  • Table 8.13: Vaica: Specifications of SimpleMedRX
  • Table 8.14: Vaica: Specifications of Capsuled™
  • Table 8.15: Vaica: Specifications of SimpleMed Suit
  • Table 8.16: Vaica: Recent Developments and Future Outlook
  • Table 11.1: Drug Adherence Enhancement Market: Funding and Investments, January 2001-August 2018
  • Table 11.2: Funding and Investment Analysis: Summary of Investments
  • Table 12.1: Drug Adherence Enhancement: Partnerships and Collaborations, 2010-2018
  • Table 13.1: Medication Adherence: List of Mobile Applications
  • Table 13.2: Medication Adherence with Mobile Applications: List of Publications
  • Table 13.3: Medication Adherence with Mobile Applications: List of Clinical Trials
  • Table 13.4: Medication Adherence with Mobile Applications: Primary and Secondary Endpoint(s), and Study Outcomes of Clinical Trials
  • Table 16.1: AceAge: Key Highlights
  • Table 16.2: AdhereTech: Key Highlights
  • Table 16.3: Amiko Digital Health: Key Highlights
  • Table 16.4: Cognita Labs: Key Highlights
  • Table 16.5: etectRx: Key Highlights
  • Table 16.6: PharmAdva: Key Highlights
  • Table 16.7: Popit Technologies: Key Highlights
  • Table 16.8: Wealth Taxi: Key Highlights
  • Table 17.1: Smart Drug Delivery Devices: Distribution of Developers by Year of Establishment
  • Table 17.2: Smart Drug Delivery Devices: Distribution of Developers by Geographical Location (Region-wise)
  • Table 17.3: Smart Drug Delivery Devices: Distribution of Developers by Geographical Location (Country-wise)
  • Table 17.4: Smart Drug Delivery Devices: Distribution of Developers by Size (Employee Count)
  • Table 17.5: Smart Drug Delivery Devices: Distribution by Type of Device
  • Table 17.6: Smart Drug Delivery Devices: Distribution by Mode of Drug Delivery
  • Table 17.7: Smart Drug Delivery Devices: Distribution by Key Specifications
  • Table 17.8: Smart Drug Delivery Devices: Distribution by Availability of Audio / Visual Reminders
  • Table 17.9: Smart Drug Delivery Devices: Distribution by Availability of Connectivity (USB, Bluetooth or Cellular)
  • Table 17.10: Smart Drug Delivery Devices: Distribution by Availability of Companion Mobile Application
  • Table 17.11: Smart Drug Delivery Devices: Distribution by Availability of Companion Mobile Application and Companion Web Portal
  • Table 17.12: Smart Drug Delivery Devices: Distribution by Availability of Companion Mobile Application and Data Storage / Cloud Platform
  • Table 17.13: Smart Drug Delivery Devices: Distribution by Battery Backup / Rechargeable Battery
  • Table 17.14: Smart Drug Delivery Devices: Key Players
  • Table 17.15: Smart Inhalers: Distribution of Developers by Year of Establishment
  • Table 17.16: Smart Inhalers: Distribution of Developers by Geographical Location
  • Table 17.17: Smart Inhalers: Distribution of Developers by Size (Employee Count)
  • Table 17.18: Smart Inhalers: Distribution by Key Device Specifications
  • Table 17.19: Smart Injectors: Distribution of Developers by Year of Establishment
  • Table 17.20: Smart Injectors: Distribution of Developers by Geographical Location
  • Table 17.21: Smart Injectors: Distribution of Developers by Size(Employee Count)
  • Table 17.22: Smart Injectors: Distribution by Key Device Specifications
  • Table 17.23: Smart Wearable Injectors: Distribution of Developers by Year of Establishment
  • Table 17.24: Smart Wearable Injectors: Distribution of Developers by Geographical Location
  • Table 17.25: Smart Wearable Injectors: Distribution of Developers by Size(Employee Count)
  • Table 17.26: Smart Wearable Injectors: Distribution by Key Device Specifications
  • Table 17.27: Smart Pills / Other Smart Devices: Distribution of Developers by Year of Establishment
  • Table 17.28: Smart Pills / Other Smart Devices: Distribution of Developers by Geographical Location
  • Table 17.29: Smart Pills / Other Smart Devices: Distribution of Developers by Size(Employee Count)
  • Table 17.30: Smart Pills / Other Smart Devices: Distribution by Key Device Specifications
  • Table 17.31: Smart Accessory Devices: Distribution of Developers by Year of Establishment
  • Table 17.32: Smart Accessory Devices: Distribution of Developers by Geographical Location(Region-wise)
  • Table 17.33: Smart Accessory Devices: Distribution of Developers by Geographical Location(Country-wise)
  • Table 17.34: Smart Accessory Devices: Distribution of Developers by Size(Employee Count)
  • Table 17.35: Smart Accessory Devices: Distribution by Type of Device
  • Table 17.36: Smart Accessory Devices: Distribution by Key Specifications
  • Table 17.37: Smart Accessory Devices: Distribution by Availability of Audio / Visual Reminders
  • Table 17.38: Smart Accessory Devices: Distribution by Availability of Connectivity(USB, Bluetooth, Wi-Fi or Cellular)
  • Table 17.39: Smart Accessory Devices: Distribution by Availability of Companion Mobile Application
  • Table 17.40: Smart Accessory Devices: Distribution by Availability of Companion Web Portal
  • Table 17.41: Smart Accessory Devices: Distribution by Availability of Data Storage / Cloud Platform
  • Table 17.42: Smart Accessory Devices: Distribution by Availability of Battery Backup / Rechargeable
  • Table 17.43: Smart Accessory Devices: Key Players
  • Table 17.44: Smart Medication Dispensers: Distribution of Developers by Year of Establishment
  • Table 17.45: Smart Medication Dispensers: Distribution of Developers by Geographical Location
  • Table 17.46: Smart Medication Dispensers: Distribution of Developers by Size(Employee Count)
  • Table 17.47: Smart Medication Dispensers: Distribution by Key Device Specifications
  • Table 17.48: Smart Pill Bottles / Caps: Distribution of Developers by Year of Establishment
  • Table 17.49: Smart Pill Bottles / Caps: Distribution of Developers by Geographical Location
  • Table 17.50: Smart Pill Bottles / Caps: Distribution of Developers by Size(Employee Count)
  • Table 17.51: Smart Pill Bottles / Caps: Distribution by Key Device Specifications
  • Table 17.52: Smart Pill Boxes: Distribution of Developers by Year of Establishment
  • Table 17.53: Smart Pill Boxes: Distribution of Developers by Geographical Location
  • Table 17.54: Smart Pill Boxes: Distribution of Developers by Size(Employee Count)
  • Table 17.55: Smart Pill Boxes: Distribution by Key Device Specifications
  • Table 17.56: Smart Blister Packs: Distribution of Developers by Year of Establishment
  • Table 17.57: Smart Blister Packs: Distribution of Developers by Geographical Location
  • Table 17.58: Smart Blister Packs: Distribution of Developers by Size(Employee Count)
  • Table 17.59: Smart Blister Packs: Distribution by Key Device Specifications
  • Table 17.60: Other Smart Devices: Distribution of Developers by Year of Establishment
  • Table 17.61: Other Smart Devices: Distribution of Developers by Geographical Location
  • Table 17.62: Other Smart Devices: Distribution of Developers by Size(Employee Count)
  • Table 17.63: Other Smart Devices: Distribution by Key Device Specifications
  • Table 17.64: Compliance Packaging Systems: Distribution of Developers by Geographical Location
  • Table 17.65: Compliance Packaging Systems: Distribution of Developers by Size(Employee Count)
  • Table 17.66: Compliance Packaging Systems: Distribution by Type of Packaging System
  • Table 17.67: Compliance Packaging Systems: Distribution by Number of Doses per Pack
  • Table 17.68: Compliance Packaging Systems: Distribution by Availability of Other Features
  • Table 17.69: Adherium: Annual Revenues, FY1516-H1 FY1718(USD Million)
  • Table 17.70: BIOCORP: Annual Revenues, 2014-2017(EUR Million)
  • Table 17.71: Ypsomed: Annual Revenues, FY1314-FY1718(CHF Million)
  • Table 17.72: Ypsomed: Sales by Business Divisions, FY1718(CHF Million)
  • Table 17.73: Philips: Annual Revenues, 2013-H1 2018(EUR Billion)
  • Table 17.74: Philips: Revenues by Business Segments, H1 2018(EUR Billion)
  • Table 17.75: Overall Product Competitiveness Analysis
  • Table 17.76: Overall Product Competitiveness Analysis: Distribution of Different Types of Products by Scores
  • Table 17.77: Funding and Investment Analysis: Cumulative Number of Instances, January 2001-August 2018
  • Table 17.78: Funding and Investment Analysis: Cumulative Amount Invested, January 2001-August 2018(USD Million)
  • Table 17.79: Funding and Investment Analysis: Distribution by Type of Funding, January 2001-August 2018
  • Table 17.80: Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, January 2001-August 2018(USD Million)
  • Table 17.81: Funding and Investment Analysis: Summary of Investments, January 2001-August 2018(USD Million)
  • Table 17.82: Funding and Investment Analysis: Distribution of Number of Funding Instances by Year of Investment and Major Device Categories, January 2001-August 2018
  • Table 17.83: Funding and Investment Analysis: Distribution of Number of Funding Instances by Type of Funding and Major Device Categories, January 2001-August 2018
  • Table 17.84: Funding and Investment Analysis: Distribution of Amount Invested by Year of Investment and Major Device Categories, January 2001-August 2018
  • Table 17.85: Funding and Investment Analysis: Most Active Players in terms of Number of Instances, January 2001-August 2018
  • Table 17.86: Funding and Investment Analysis: Most Active Players in Terms of Amount Raised(USD Million), January 2001-August 2018
  • Table 17.87: Funding and Investment Analysis: Most Active Investors
  • Table 17.88: Funding and Investment Summary
  • Table 17.89: Partnerships and Collaborations: Distribution by Year, 2010-2018
  • Table 17.90: Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 17.91: Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Table 17.92: Partnerships and Collaborations: Most Active Players
  • Table 17.93: Partnerships and Collaborations: Distribution by Type and Year of Partnership
  • Table 17.94: Partnerships and Collaborations: Distribution by Type and Geographical Presence of Companies
  • Table 17.95: Partnerships and Collaborations: Regional Distribution
  • Table 17.96: Medication Adherence Clinical Trial Publications for Software Applications: Distribution by Therapeutic Areas
  • Table 17.97: Global Drug Adherence Enhancement Market, Conservative, Base and Optimistic Scenarioss, Scenarios2018-2030(USD Billion)
  • Table 17.98: Drug Adherence Enhancement Market for Smart Drug Delivery Devices, Conservative, Base and Optimistic Scenarios, Scenarios2018-2030(USD Billion)
  • Table 17.99: Drug Adherence Enhancement Market for Smart Accessory Devices, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.100: Drug Adherence Enhancement Market for Other Type of Devices, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.101: Global Drug Adherence Enhancement Market, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.102: Digital Drug Adherence Enhancement Market for Smart Drug Delivery Devices, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.103: Drug Adherence Enhancement Market for Smart Accessory Devices, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.104: Drug Adherence Enhancement Market for Other Type of Devices, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.105: Drug Adherence Enhancement Market in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.106: Drug Adherence Enhancement Market in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.107: Drug Adherence Enhancement Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.108: Drug Adherence Enhancement Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.109: Drug Adherence Enhancement Market for Smart Inhalers, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.110: Drug Adherence Enhancement Market for Smart Inhalers in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.111: Drug Adherence Enhancement Market for Smart Inhalers in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.112: Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.113: Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.114: Drug Adherence Enhancement Market for Smart Injectors, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.115: Drug Adherence Enhancement Market for Smart Injectors in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.116: Drug Adherence Enhancement Market for Smart Injectors in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.117: Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.118: Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.119: Drug Adherence Enhancement Market for Smart Wearable Injectors, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.120: Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.121: Digital Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.122: Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.123: Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.124: Drug Adherence Enhancement Market for Smart Pills, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.125: Drug Adherence Enhancement Market for Smart Pills in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.126: Drug Adherence Enhancement Market for Smart Pills in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.127: Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.128: Drug Adherence Enhancement Market for Smart Pills in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.129: Drug Adherence Enhancement Market for Smart Medication Dispensers, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.130: Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.131: Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.132: Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.133: Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.134: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.135: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.136: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.137: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.138: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.139: Drug Adherence Enhancement Market for Smart Blister Packs, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.140: Drug Adherence Enhancement Market for Smart Blister Packs in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.141: Drug Adherence Enhancement Market for Smart Blister Packs in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.142: Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.143: Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.144: Drug Adherence Enhancement Market for Other Type of Products, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.145: Drug Adherence Enhancement Market for Other Type of Products in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.146: Drug Adherence Enhancement Market for Other Type of Products in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.147: Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.148: Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.149: Drug Adherence Enhancement Market for Smart Inhalers, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.150: Drug Adherence Enhancement Market for Smart Inhalers in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.151: Drug Adherence Enhancement Market for Smart Inhalers in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.152: Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.153: Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.154: Drug Adherence Enhancement Market for Smart Injectors, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.155: Drug Adherence Enhancement Market for Smart Injectors in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.156: Drug Adherence Enhancement Market for Smart Injectors in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.157: Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.158: Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.159: Drug Adherence Enhancement Market for Smart Wearable Injectors, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.160: Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.161: Digital Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.162: Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.163: Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.164: Drug Adherence Enhancement Market for Smart Pills, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.165: Drug Adherence Enhancement Market for Smart Pills in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.166: Drug Adherence Enhancement Market for Smart Pills in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.167: Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.168: Drug Adherence Enhancement Market for Smart Pills in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.169: Drug Adherence Enhancement Market for Smart Medication Dispensers, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.170: Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.171: Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.172: Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.173: Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.174: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.175: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.176: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.177: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.178: Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.179: Drug Adherence Enhancement Market for Smart Blister Packs, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.180: Drug Adherence Enhancement Market for Smart Blister Packs in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.181: Drug Adherence Enhancement Market for Smart Blister Packs in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.182: Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.183: Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.184: Drug Adherence Enhancement Market for Other Type of Products, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.185: Drug Adherence Enhancement Market for Other Type of Products in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.186: Drug Adherence Enhancement Market for Other Type of Products in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.187: Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.188: Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.189: Drug Adherence Enhancement Market for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.190: Drug Adherence Enhancement Market for Metabolic Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.191: Drug Adherence Enhancement Market for Metabolic Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.192: Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.193: Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.194: Drug Adherence Enhancement Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.195: Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.196: Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.197: Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.198: Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.199: Drug Adherence Enhancement Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.200: Drug Adherence Enhancement Market for Respiratory Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.201: Drug Adherence Enhancement Market for Respiratory Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.202: Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.203: Drug Adherence Enhancement Market for Respiratory Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.204: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.205: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.206: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.207: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.208: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.209: Drug Adherence Enhancement Market for Other Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.209: Drug Adherence Enhancement Market for Other Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.210: Drug Adherence Enhancement Market for Other Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.211: Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.212: Drug Adherence Enhancement Market for Other Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.213: Drug Adherence Enhancement Market for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.214: Drug Adherence Enhancement Market for Metabolic Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.215: Drug Adherence Enhancement Market for Metabolic Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.216: Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.217: Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.218: Drug Adherence Enhancement Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.219: Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.220: Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.221: Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.222: Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.223: Drug Adherence Enhancement Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.224: Drug Adherence Enhancement Market for Respiratory Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.225: Drug Adherence Enhancement Market for Respiratory Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.226: Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.227: Drug Adherence Enhancement Market for Respiratory Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.228: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.229: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.230: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.231: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.232: Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.233: Drug Adherence Enhancement Market for Other Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.234: Drug Adherence Enhancement Market for Other Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.235: Drug Adherence Enhancement Market for Other Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.236: Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.237: Drug Adherence Enhancement Market for Other Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.238: Drug Adherence Enhancement Market for Products Intended for Oral Medications, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.239: Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.240: Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.241: Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.242: Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.243: Drug Adherence Enhancement Market for Products Intended for Injectables, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.244: Drug Adherence Enhancement Market for Products Intended for Injectables in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.245: Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.246: Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.247: Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.248: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.249: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.250: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.251: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.252: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.253: Drug Adherence Enhancement Market for Products Intended for Other Medications, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.254: Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.255: Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.256: Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.257: Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(USD Billion)
  • Table 17.258: Drug Adherence Enhancement Market for Products Intended for Oral Medications, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.259: Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.260: Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.261: Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.262: Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.263: Drug Adherence Enhancement Market for Products Intended for Injectables, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.264: Drug Adherence Enhancement Market for Products Intended for Injectables in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.265: Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.266: Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.267: Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.268: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.269: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.270: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.271: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.272: Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.273: Drug Adherence Enhancement Market for Products Intended for Other Medications, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.274: Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.275: Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.276: Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)
  • Table 17.277: Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030(Units, Million)

Listed Companies:

The following companies and organizations have been mentioned in the report:

  • 1. 3M
  • 2. 5AM Ventures
  • 3. 7wire Ventures
  • 4. 91streets Media Technologies
  • 5. AARDEX Group
  • 6. AARP
  • 7. Abbott
  • 8. Abiogenix
  • 9. AceAge
  • 10. Acintyo
  • 11. Acta Distribution
  • 12. ActiveCare
  • 13. Adams Street Partners
  • 14. AdhereTech
  • 15. Adherium
  • 16. Administración Nacional de Medicamentos, Alimentosy Tecnología Médica
  • 17. Advent Venture Partners
  • 18. Aerobit Health
  • 19. AeroSonix
  • 20. Agência Nacional de Vigilância Sanitária (National Health Surveillance Agency)
  • 21. Aguettant
  • 22. Air Liquide Healthcare
  • 23. AIRBRIO
  • 24. Airnest
  • 25. Allscripts
  • 26. Altran
  • 27. Amarutek
  • 28. Amazon
  • 29. AMC Health
  • 30. American Academy of Allergy, Asthma and Immunology
  • 31. American Heart Association
  • 32. Amerigroup
  • 33. Amgen
  • 34. Amiko Digital Health
  • 35. ANTARGYAN CLOUDWORKS
  • 36. ApnaCare India
  • 37. Apollo Diabetes Care Management
  • 38. Apolotus Health Solution
  • 39. Apoteket
  • 40. App Singularity
  • 41. AppAttic
  • 42. Appgraid Apps
  • 43. AppQuik
  • 44. AppTrailz
  • 45. Aptar Pharma
  • 46. Area9 Innovation
  • 47. Arthur Health
  • 48. Artmedus
  • 49. ARTORG Center
  • 50. AS PHARM SOFT
  • 51. Asheville Angels
  • 52. Asho Soft Tech
  • 53. Asset Management Ventures
  • 54. Asthma and Respiratory Foundation New Zealand
  • 55. AstraZeneca
  • 56. AT&T
  • 57. Aterica Digital Health
  • 58. August Faller Group
  • 59. Auriga Partners
  • 60. Australasian Medical & Scientific
  • 61. Austrian Chamber of Pharmacists
  • 62. Automated Security Alert
  • 63. Aventyn
  • 64. Avery Dennison Medical Solutions
  • 65. Avnet Integrated Solutions
  • 66. Baviux
  • 67. Bayer
  • 68. Becton Dickinson
  • 69. BERG
  • 70. Bigfoot Biomedical
  • 71. BioAdvance
  • 72. BioAssist
  • 73. BIOCORP
  • 74. BioMark Health
  • 75. BioScience Managers
  • 76. BIVA
  • 77. BlackPearls
  • 78. Blackberry
  • 79. Blueprint Health
  • 80. Boehringer Ingelheim
  • 81. Bosch
  • 82. Brain Tech
  • 83. Brainovations Education Excellence
  • 84. Breed Reply
  • 85. Butterfly Ventures
  • 86. C-Square Info Solutions
  • 87. C3HealthLink
  • 88. caiocrol
  • 89. California HealthCare Foundation
  • 90. California Highlands Addiction Treatment
  • 91. Cambridge Enterprise
  • 92. Cambridge Consultants
  • 93. Canada Innovation Acceleration Investment
  • 94. Capital Angels
  • 95. Capital Royalty Partners II
  • 96. Cardinal Health
  • 97. CareCentra
  • 98. CareConsult
  • 99. CareZone
  • 100. Catalent Pharma Solutions
  • 101. Celgene
  • 102. Cellnovo
  • 103. Cenduit
  • 104. Centers for Disease Control and Prevention
  • 105. Centers for Medicare & Medicaid Services
  • 106. Central Drugs Standard Control Organization
  • 107. Centric Health
  • 108. Chalmers Ventures
  • 109. CheckTheMeds Technology
  • 110. Children's Hospital of Philadelphia
  • 111. China Food and Drug Administration
  • 112. CHORDAS
  • 113. Chronicare
  • 114. Cigna Health Insurance
  • 115. Cincinnati Children's Hospital Medical Center
  • 116. Circadian Design
  • 117. Clifton R Farris
  • 118. CML Advocates Network
  • 119. Cognita Labs
  • 120. Cognitive Healthcare
  • 121. Cohero Health
  • 122. Colbert Packaging
  • 123. Comisión Federal para la Protección contra Riesgos Sanitarios
  • 124. Common Sensing
  • 125. Community Care Network of Virginia
  • 126. Companion Medical
  • 127. Compliance Meds Technologies
  • 128. Confrérie Clinique
  • 129. Connecticut Children's Medical Center
  • 130. Core Mobile
  • 131. Credit Agricole Private Equity
  • 132. Crux Product Design
  • 133. CSL Behring
  • 134. C Square Info Solutions
  • 135. CUCO Health
  • 136. CuePath Innovation
  • 137. Curatio
  • 138. Curis
  • 139. Cyft
  • 140. DayaMed
  • 141. Debiotech
  • 142. Decision Machines
  • 143. DeepBench
  • 144. Delphi Ventures
  • 145. Desert Oasis Healthcare
  • 146. DeskShare
  • 147. Dexcom
  • 148. Diabeloop
  • 149. Diasend
  • 150. Digital Pharmacist
  • 151. Diplomat Pharmacy
  • 152. Disetronic Group
  • 153. Dispill-USA
  • 154. DistriMedic
  • 155. DocRoSh Health
  • 156. Domain Associates
  • 157. Dosecast
  • 158. DoseCue
  • 159. DoseSmart
  • 160. DOTh Solutions
  • 161. Douglas Pharmaceuticals
  • 162. Drug Package
  • 163. Duke University
  • 164. DYN Diagnostics
  • 165. EcoloPharm
  • 166. Edmond de Rothschild
  • 167. E Ink
  • 168. Elcam Drug Delivery Devices (E3D)
  • 169. Eli Lilly
  • 170. Elkstone Capital Partners
  • 171. EMedStore Pharma IT
  • 172. emocha Mobile Health
  • 173. Emperra E-Health Technologies
  • 174. Enable Injections
  • 175. Enercon Technologies
  • 176. EnvoyHealth
  • 177. Essex Woodlands
  • 178. etectRx
  • 179. ETHIO APPS
  • 180. Eularis
  • 181. European Investment Bank
  • 182. European Medicines Agency
  • 183. Evalan
  • 184. Everwell Health Solutions
  • 185. Everwin Precision Technology
  • 186. Evondos
  • 187. Excell Partners
  • 188. Experts in Communications and Connectivity Technology (ECCT)
  • 189. Express Scripts
  • 190. Fagor Healthcare
  • 191. Fedefarma
  • 192. Fidelity International
  • 193. FindAir
  • 194. The Finnish Funding Agency for Technology and Innovation
  • 195. Fletcher Spaght Ventures
  • 196. Flex
  • 197. Forbion Capital Partners
  • 198. Frost & Sullivan
  • 199. GalileoMD
  • 200. Gecko Health Innovations
  • 201. GenieMD
  • 202. Genome BC
  • 203. GIS Strategic Ventures
  • 204. GlaxoSmithKline
  • 205. Global Emerging Markets Group
  • 206. Gloria Pharmaceuticals
  • 207. GlucoRx
  • 208. GoSmart
  • 209. GoodCare Pharma
  • 210. GoodRx
  • 211. GoodVent Beteiligungsmanagement
  • 212. H&T Presspart
  • 213. H&Y Apps
  • 214. Hackensack Meridian Health
  • 215. HAP Innovations
  • 216. Haselmeier
  • 217. HCL Technologies
  • 218. Health Bot
  • 219. Health Canada
  • 220. Health Care Originals
  • 221. Health Department of Oslo
  • 222. Health Mission
  • 223. Health Monitor
  • 224. HealthBeacon
  • 225. Healthbox
  • 226. HealthCare Ventures
  • 227. Healthcom
  • 228. Healtheoz
  • 229. Healthio
  • 230. HealthPrize Technologies
  • 231. Health's Angel
  • 232. Heitkamp & Thumann Group
  • 233. Helmer Scientific
  • 234. Hepatitis Victoria
  • 235. HERO Health
  • 236. Hexoskin
  • 237. Hikma Ventures
  • 238. Home Diagnostics
  • 239. HP Labs
  • 240. HTC
  • 241. Human API
  • 242. Humana
  • 243. IAP Labs
  • 244. IDEAL LIFE
  • 245. ImageWare Systems
  • 246. ImagineCare
  • 247. Immunex
  • 248. Information Mediary
  • 249. Innospence
  • 250. Innovation Zed
  • 251. INRange Systems
  • 252. Inspirit Innovations
  • 253. Insulin Pump Hellas
  • 254. Intelligent Devices SEZC
  • 255. Intelligent Product Solutions
  • 256. Intent Solutions
  • 257. International Diabetes Federation
  • 258. International Federation of Pharmaceutical Manufacturers and Associations
  • 259. Intigate Technologies
  • 260. Investitionsbank des Landes Brandenburg
  • 261. Irody
  • 262. IRWAA
  • 263. iSense
  • 264. ITmedicus
  • 265. Itochu
  • 266. IVAX
  • 267. Jabil
  • 268. Janssen Pharmaceutica
  • 269. JDRF
  • 270. Jiangsu Delfu Medical Device
  • 271. Jones Packaging
  • 272. Joslin Diabetes Center
  • 273. Journey Health Labs
  • 274. JVS Technologies
  • 275. Kaiser Permanente Ventures
  • 276. KCRise Fund
  • 277. Keystone Folding Box
  • 278. Konkuk University
  • 279. Korl Medical Center
  • 280. Kreos Capital
  • 281. K-svets
  • 282. Kuwait Investment Authority
  • 283. Life Integrating Technologies and Experiences (LITE)
  • 284. Life Sciences Angel Network
  • 285. LifeMatters
  • 286. LloydsPharmacy
  • 287. Lohmann Therapie Systeme
  • 288. lool Ventures
  • 289. Lowcountry Angels
  • 290. LoyAlerts
  • 291. LSDinfotech
  • 292. Luz Saúde
  • 293. M Ventures
  • 294. M2M Datasmart
  • 295. Maangata Apps
  • 296. Maccabi Healthcare Services
  • 297. Mail-Meds
  • 298. Maj Invest Equity
  • 299. Manchac Technologies
  • 300. Mango Health
  • 301. Manrex
  • 302. Manyeta
  • 303. MAP Health Management
  • 304. Marketaro
  • 305. MassChallenge
  • 306. Maxerence
  • 307. McKesson
  • 308. MeadWestvaco
  • 309. MedApps
  • 310. MedControl Technologies
  • 311. MedCrypt
  • 312. Medexpert
  • 313. Medical International Research
  • 314. Medical Research Institute of New Zealand
  • 315. Medical Specialties Australia
  • 316. Medication Solutions
  • 317. Medicine-On-Time
  • 318. Medico Pak
  • 319. Medicom Innovation Partner
  • 320. MedicPen
  • 321. Medimate
  • 322. Medipense
  • 323. Medisafe
  • 324. MedMinder Systems
  • 325. Medocity
  • 326. MedPak Pharmacy
  • 327. MedReady
  • 328. MedSmart
  • 329. Medtronic
  • 330. Medtrum
  • 331. MENA Apps
  • 332. Merck
  • 333. Metro Health
  • 334. Mevia
  • 335. MicroHealth
  • 336. Ministry of Food and Drug Safety
  • 337. Ministry of Health, Labour and Welfare
  • 338. MivaTek Smart Connect
  • 339. Molina Healthcare
  • 340. Montuno Software
  • 341. Mount Sinai Health System
  • 342. Movi
  • 343. MphRx
  • 344. Multiframes
  • 345. Mylan
  • 346. MyMeds
  • 347. MyTherapy
  • 348. NantHealth
  • 349. Nath IT Solutions
  • 350. National Competent Authority
  • 351. National Consumers League
  • 352. National Institutes of Health
  • 353. National Institute of Mental Health (NIMH)
  • 354. Navia Life Care
  • 355. NaviMed
  • 356. NBGI Ventures
  • 357. NECTEC
  • 358. Nemera
  • 359. NESTA
  • 360. Nestlé Health Science
  • 361. New Directions Technology Consulting
  • 362. New World Health
  • 363. New Zealand Medical & Scientific
  • 364. NexusLink Services
  • 365. nGageIT Digital Medicine
  • 366. Noble International
  • 367. NOPII
  • 368. Novalab Ibérica
  • 369. Novartis
  • 370. Novo Nordisk
  • 371. Now Healthcare Group
  • 372. NPS MedicineWise
  • 373. Octopus Ventures
  • 374. Office of the National Coordinator for Health Information Technology Omnicell
  • 375. Omron Healthcare
  • 376. One Drop
  • 377. Onward Care Technologies
  • 378. Oracle Health Sciences
  • 379. Orbita
  • 380. ORI Healthcare Fund
  • 381. Otsuka Pharmaceutical
  • 382. Oxford Finance
  • 383. Oyster Capital Partners
  • 384. P5 Health Ventures
  • 385. Palladio Group
  • 386. Parata Systems
  • 387. Partners HealthCare
  • 388. PatientPartner
  • 389. PBJ Capital
  • 390. Pear Therapeutics
  • 391. Pegasystems
  • 392. Peppermint VenturePartners
  • 393. PhableCare
  • 394. Pharmacell Medication Systems
  • 395. Pharmaceutical and Medical Devices Agency
  • 396. PharmAdva
  • 397. PharmaSens
  • 398. PharmRight
  • 399. Philips
  • 400. Phillips-Medisize
  • 401. Phoenix Healthcare
  • 402. Picomol Healthcare
  • 403. PillDrill
  • 404. Pillo Health
  • 405. PillPack
  • 406. Pitango Venture Capital
  • 407. Play-it Health
  • 408. PMA Pharmacy
  • 409. Poliweb Graphics
  • 410. Popit
  • 411. Portal Instruments
  • 412. Practo
  • 413. Prescription Notification Group
  • 414. Prescription Solutions
  • 415. ProCare Rx
  • 416. Propeller Health
  • 417. Proteus Digital Health
  • 418. PRPL
  • 419. Qualcomm Life
  • 420. Quantum Pharmaceutical
  • 421. Quido Healthcare Services
  • 422. QuiO Technologies
  • 423. Quizora Media
  • 424. Raffles Medical Group
  • 425. Ramtin Software Solutions
  • 426. Raneem Technologies
  • 427. Recovery Centers of America
  • 428. RemindTrac
  • 429. Renata
  • 430. Research Institute of the McGill University Health Centre
  • 431. Resolve Digital Health
  • 432. Respia
  • 433. Rex Medical
  • 434. Risk Cooperative
  • 435. Robert Bosch Venture Capital
  • 436. Roche
  • 437. RockTenn
  • 438. Rubin Medical
  • 439. RxAdvance
  • 440. RxNetworks
  • 441. RXVIP Concierge
  • 442. Safeguard Scientifics
  • 443. Safeway
  • 444. Sagentia
  • 445. Samsung
  • 446. Samsung NEXT
  • 447. Sanner Group
  • 448. Sanofi
  • 449. Sanofi-Sunrise
  • 450. Saudi Food and Drug Authority
  • 451. Schreiner MediPharm
  • 452. SCRA Technology
  • 453. Second Technology Capital Investors
  • 454. SentiCare
  • 455. Seoul National University
  • 456. Serendipity Partners
  • 457. SHL Group
  • 458. Silicon Valley Bank
  • 459. Simplified APP Solutions
  • 460. Sino Portfolio
  • 461. Sinwho
  • 462. SmarterHealth TechServe
  • 463. Smartgateways
  • 464. Smiths Medical
  • 465. Smooth Apps Studio
  • 466. SMRxT
  • 467. Social Capital
  • 468. Soft Industry Alliance
  • 469. Sonceboz
  • 470. SOOIL Development
  • 471. South Carolina Angel Network
  • 472. Spartanburg Angels
  • 473. Spring Ridge Ventures
  • 474. Sprint
  • 475. Spyzar Studios
  • 476. SR One
  • 477. St. Helena Health
  • 478. St. Jude Medical
  • 479. STAAR Alert
  • 480. Sunrise Labs
  • 481. SuperAndroidApp
  • 482. Swanhill Capital
  • 483. Syqe Medical
  • 484. Takeda Pharmaceutical
  • 485. Tandem Diabetes Care
  • 486. TCGRx
  • 487. Techizer Tech Solutions
  • 488. Tekes
  • 489. TerraNovita
  • 490. Teva Pharmaceutical
  • 491. The Carlyle Group
  • 492. The Cyto Cord Group
  • 493. The Kroger
  • 494. Therapeutic Goods Administration
  • 495. Three Leaf Ventures
  • 496. Tidepool
  • 497. Tillotts Pharma
  • 498. TimerCap
  • 499. Tinylogics
  • 500. Tonghua Dongbao Pharmaceutical
  • 501. TowerView Health
  • 502. TPG Biotech
  • 503. Triad HealthCare Network
  • 504. Tricella
  • 505. Trinnovate Ventures
  • 506. TriVentures
  • 507. TypeZero Technologies
  • 508. UNICUS HealthReach
  • 509. United Family Healthcare
  • 510. United States Food and Drug Administration
  • 511. UnitedHealthcare
  • 512. University of Cambridge
  • 513. University of Arkansas for Medical Sciences
  • 514. University of Toronto
  • 515. University of Pittsburgh Medical Center
  • 516. Urtech Manufacturing
  • 517. Vaica
  • 518. Valtronic
  • 519. Vectura Group
  • 520. Verizon Investments
  • 521. Virbac
  • 522. Vishnu Global Services
  • 523. Vitalus Health
  • 524. Walgreens
  • 525. Waterline Ventures
  • 526. Wcre8tive App Developer
  • 527. Wealth Taxi
  • 528. Web Coast Apps
  • 529. Welkin Health
  • 530. West Pharmaceutical Services
  • 531. WestRock
  • 532. Whisper Arts
  • 533. WMM
  • 534. World Allergy Organization
  • 535. World Health Organization
  • 536. WorldMedic
  • 537. Wyeth-Ayerst Pharmaceuticals
  • 538. Xcenda
  • 539. Xhale
  • 540. Ximedica
  • 541. XINK Laboratories
  • 542. YOURmeds
  • 543. YPSOMED
  • 544. Zaffre Investments
  • 545. Zibdy
  • 546. Zipit Wireless
Back to Top